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1. INTRODUCTION 
TUBERCULOSIS- AN INSIGHT  
Tuberculosis, MTB, or TB (short for tubercle bacillus) is a common, and in 
many cases lethal, infectious disease caused by various strains of mycobacteria, usually 
Mycobacterium tuberculosis. Tuberculosis typically attacks the lungs, but can also 
affect other parts of the body. It is spread through the air when people, who have an 
active TB infection, cough, sneeze, or otherwise transmit their saliva through the air. 
Most infections are asymptomatic and latent, but about one in ten latent infections 
eventually progresses to active disease which, if left untreated, kills more than 50% of 
those so infected.  
Consumption, phthisis, scrofula, Pott's disease, and the White Plague are all 
terms used to refer to tuberculosis throughout history. It is generally accepted that the 
microorganism originated from other, more primitive organisms of the same genus 
Mycobacterium. Human bones from the Neolithic show  presence of the bacteria, 
although the exact magnitude (incidence and prevalence) is not known before the 19th 
century.  
The first references to tuberculosis in Asian civilization are found in the Vedas. 
The oldest of them (Rigveda, 1500 BC) calls the disease yaksma. The Atharvaveda calls 
it another name: balasa. It is in the Atharvaveda that the first description of scrofula is 
given. The Sushruta Samhita, written around 600 BC, recommends that the disease be 
treated with breast milk, various meats, alcohol and rest. The Yajurveda advises 
sufferers to move to higher altitudes.  
Aretaeus was the first person to rigorously describe the symptoms of the disease 
in his text De causis et signis diuturnorum morborum: 
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“Voice hoarse; neck slightly bent, tender, not flexible, somewhat extended; 
fingers slender, but joints thick; of the bones alone the figure remains, for the fleshy 
parts are wasted; the nails of the fingers crooked, their pulps are shriveled and 
flat...Nose sharp, slender; cheeks prominent and red; eyes hollow, brilliant and 
glittering; swollen, pale or livid in countenance; the slender parts of the jaws rest on the 
teeth as, as if smiling; otherwise of cadaverous aspect...”
 [1] [2]  
PATHOGENESIS OF TUBERCULOSIS  
M. tuberculosis usually enters the alveolar passages of exposed humans in an 
aerosol droplet, where its first contact is thought be with resident macrophages, but it is 
also possible that bacteria can be initially ingested by alveolar epithelial type II 
pneumocytes. This cell type is found in greater numbers than macrophages in alveoli, 
and M. tuberculosis can infect and grow in these pneumocytes ex vivo.  
In addition, dendritic cells play a very important  role in the early stages of 
infection since they are much better antigen presenters than are macrophages and 
presumably play a key role in activating T cells with specific M. tuberculosis antigens. 
Since dendritic cells are migratory, unlike differentiated macrophages, they also may 
play an important role in dissemination of M. tuberculosis.  
The bacteria are phagocytosed in a process that is initiated by bacterial contact 
with macrophage mannose and/or complement receptors. Surfactant protein A, a 
glycoprotein found on alveolar surfaces, can enhance the binding and uptake of M. 
tuberculosis by up regulating mannose receptor activity.  
On the other hand, surfactant protein D, similarly located in alveolae, inhibits 
phagocytosis of M.tuberculosis by blocking mannosyl oligosaccharide residues on the  
bacterial cell surface, and it is proposed that this prevents M.tuberculosis interaction 
with mannose receptors on the macrophage cell surface.  The human toll-like receptor 
2 (TLR2) also plays a role in M. tuberculosis uptake. 
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On entry into a host macrophage, M. tuberculosis resides in an endocytic 
vacuoule called the phagosome. If the normal phagosomal maturation cycle 
occurs, i.e., phagosome-lysosome fusion, these bacteria can encounter a hostile 
environment that includes acid pH, reactive oxygen intermediates (ROI), 
lysosomal enzymes, and toxic peptides. The presence of RNIs in human 
macrophages and their potential role in disease has been the subject of 
controversy, but the alveolar macrophages of a majority of TB-infected patients 
exhibit iNOS activity.
 [1]
 
 
Fig 01 - Pathogenetic Pathway of tuberculosis infection 
 
CELL WALL STRUCTURE 
The cell wall structure of Mycobacterium tuberculosis deserves special attention 
because it is unique among prokaryotes, and it is a major determinant of virulence for 
the bacterium. The cell wall complex contains peptidoglycan, but otherwise it is 
composed of complex lipids. Over 60% of the mycobacterium cell wall is lipid.  
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The lipid fraction of MTB's cell wall consists of three major components, 
mycolic acids, cord factor, and waxD. 
Mycolic  acids  are  unique  alpha  branched  lipids  found  in  cell  walls  of  
Mycobacterium  and Corynebacterium. They make up 50% of the dry weight of the 
mycobacterial cell envelope. Mycolic acids are strong hydrophobic molecules that form 
a lipid shell around the organism and affect permeability properties at the cell surface. 
Mycolic Acids are thought to be a significant determinant of virulence in MTB. 
Probably, they prevent attack of the mycobacteria by cationic proteins, lysozyme, and 
oxygen radicals in the phagocytic granule.  
Cord Factor is responsible for the serpentine cording mentioned above. Cord 
factor is toxic to mammalian cells and is also an inhibitor of PMN migration. Cord 
factor is most abundantly produced in virulent strains of MTB.  
WaxD in the cell envelope is the major component of Freund's complete adjuvant 
(CFA).
 [3]
  
 
Figure 02: Cell Wall Structure of Mycobacterium tuberculosis
[4] 
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MODE OF TRANSMISSION 
When people with active pulmonary TB cough, sneeze, speak, sing, or spit, they 
expel infectious aerosol droplets 0.5 to 5.0 µm in diameter. A single sneeze can release up 
to 40,000 droplets. Each one of these droplets may transmit the disease, since the infectious 
dose of tuberculosis is very small (the inhalation of fewer than 10 bacteria may cause an 
infection). 
People with prolonged, frequent, or close contact with people with TB are at 
particularly high risk of becoming infected, with an estimated 22% infection rate. A person 
with active but untreated tuberculosis may infect 10–15 (or more) other people per year. 
Transmission  occurs from only people with active TB – those with latent infection are not 
thought to be contagious. The probability of transmission from one person to another 
depends upon several factors, including the number of infectious droplets expelled by the 
carrier, the effectiveness of ventilation, the duration of exposure, the virulence of the M. 
tuberculosis strain, the level of immunity in the uninfected person, and others. The cascade 
of person-to-person spread can be circumvented by effectively segregating those with 
active ("overt") TB and putting them on anti-TB drug regimens. After about two weeks of 
effective treatment, subjects with nonresistant active infections generally do not remain 
contagious to others. If someone does become infected, it typically takes three to four 
weeks before the newly infected person becomes infectious enough to transmit the disease 
to others.
 [5] 
SIGNS AND SYMPTOMS OF ACTIVE TUBERCULOSIS 
1. Coughing that lasts three or more weeks.  
2. Coughing up blood. 
3. Chest pain or pain with breathing or coughing 
4. Unintentional weight loss 
5. Fatigue 
6. Fever 
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7. Night sweats and Chills 
8. Loss of apetite
[6]
 
EPIDEMIOLOGY 
One-third of the world's population is thought to have been infected with M. 
tuberculosis, with new infections occurring in about 1% of the population each year. In 
2007, an estimated 13.7 million chronic cases were active globally, while in 2013, an 
estimated 9 million new cases and 1.5 absolute number of tuberculosis cases has been 
decreasing since 2006, and new cases have decreased since 2002. The rate of tuberculosis 
in different areas varies across the globe; about 80% of the population in many Asian and 
African countries tests positive in tuberculin tests, while only 5–10% of the United States 
population tests positive. More people in the developing world contract tuberculosis 
because of a poor immune system, largely due to high rates of HIV infection and the 
corresponding development of AIDS
. 
 
TB disease most commonly affects the lungs; this is referred to as pulmonary TB 
disease. In 2009, 71% of TB cases in the United States were exclusively pulmonary. 
Patients with pulmonary TB disease usually have a cough and an abnormal chest 
radiograph, and may be infectious. Although the majority of TB cases are pulmonary, TB 
can occur in almost any anatomical site or as disseminated disease. 
Persons with LTBI have M. tuberculosis in their bodies, but do not have TB disease 
and cannot spread the infection to other people. In some people, the tubercle bacilli 
overcome the immune system and multiply, resulting in progression from LTBI to TB 
disease. 
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) 
strains of M. tuberculosis has challenged conventional anti-TB therapy and threatens global 
disease control of TB. The development of new anti-TB drugs is urgently required. β-
lactams are effective antibiotics widely used to treat bacterial infections; however, so far 
no effective anti-TB antibiotics have emerged from this class of drugs.
 [7] [8] 
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TYPES OF TUBERCULOSIS:  
Tuberculosis is a contagious disease that affects almost all the important organs 
of the body. Clinically, tuberculosis is broadly categorized into three major categories  
Primary Tuberculosis  
When tuberculosis affects a person who had never been exposed to the bacterium 
earlier, the condition is called primary tuberculosis. In this form of tuberculosis, the 
source of bacterium is external. In primary tuberculosis the lymph nodes get affected 
leading to their swelling. Lesions are also formed which are removed during treatment. 
The removal of the lesion does not indicate bacterial removal as the bacteria may have 
gone into a dormant phase and if left untreated, it can cause TB when favourable 
condition comes.  
Secondary Tuberculosis  
It is also known as post-primary tuberculosis. This type of tuberculosis occurs in 
a person who previously had TB. In primary TB, the bacterium goes into an inactive 
phase while in secondary tuberculosis; the bacterium regains its active mode and causes 
the symptoms. Secondary tuberculosis is mostly localized to lungs as oxygen pressure is 
highest there. Secondary tuberculosis is more infectious than primary tuberculosis. 
Secondary TB increases the chance of the infection’s spread to other organs such as 
kidneys, heart and brain.  
Disseminated Tuberculosis  
Disseminated tuberculosis means that the tuberculosis has infected the entire 
body system. It is a very rare type of disease. Disseminated TB primarily affects the 
bones of spines, hips, joints and knees, the genital tract of women, the urinary tract and 
even the central nervous system. It infects the cerebrospinal fluids, the gastrointestinal 
tract, the adrenal gland, skin of the neck and even the heart.  
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Miliary Tuberculosis  
It is the most severe type of tuberculosis infection. Whole of the blood stream 
gets infected with the bacterium. Numerous tiny lesions appear throughout the body. If 
the infection reaches bone marrow, it can cause anaemia. The infection in the blood 
causes uncontrolled multiplication of white blood cells, thereby leading to leukaemia -
like conditions.  
 
Fig 03-Scanning Electron Microscopic Image of M.tuberculosis 
 
 
 
Fig 04- Acid-Fast staining showing caseating granulomas containing Langhans 
giant cells, which have a "horseshoe" pattern of nuclei  
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SCIENTIFIC CLASSIFICATION
[10] 
KINGDOM Bacteria 
PHYLUM Actinobacteria 
CLASS Actinobacteria 
ORDER Actinomycetales 
SUB ORDER Corynebacterineae 
FAMILY Mycobacteriaceae 
GENUS Mycobacterium 
SPECIES Tuberculosis 
 
GENOME
 
 
The genome of the H37Rv strain was published in 1998. Its size is 4 million base 
pairs, with 3959 genes; 40% of these genes have had their function characterized, with 
possible function postulated for another 44%. Within the genome are also six 
pseudogenes. 
The genome contains 250 genes involved in fatty acid metabolism, with 39 of 
these involved in the polyketide metabolism generating the waxy coat. Such large 
numbers of conserved genes show the evolutionary importance of the waxy coat to 
pathogen survival. 
About 10% of the coding capacity is taken up by the PE/PPE gene families that encode 
acidic, glycine-rich proteins. These proteins have a conserved N-terminal motif, deletion of 
which impairs growth in macrophages and granulomas. Nine noncoding sRNAs have been 
characterized in M.tuberculosis, with a further 56 predicted in a bioinformatics screen.
 [9]  
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AN  INTRODUCTION  TO  DIAMINOPIMELATE DECARBOXYLASE 
(LysA) 
Introduction 
Pyridoxal-dependent decarboxylases that act on ornithine-, lysine-, arginine- and 
related substrates can be classified into different families on the basis of sequence 
similarity. One of these families includes ornithine decarboxylase (ODC), which 
catalyses the transformation of ornithine into putrescine; prokaryotic diaminopimelate 
decarboxylase, which catalyses the conversion of diaminopimelate into lysine; 
Pseudomonas syringae pv. tabaci protein, tabA, which is probably involved in tabtoxin 
biosynthesis and is similar to diaminopimelate decarboxylase; and bacterial and plant 
biosynthetic arginine decarboxylase, which catalyses the transformation of arginine into 
agmatine, the first step in putrescine synthesis from arginine.  
Although these proteins, which are known collectively as group IV 
decarboxylases probably share a common evolutionary origin, their levels of sequence 
similarity are low, being confined to a few short conserved regions. These conserved 
motifs suggest a common structural arrangement for positioning of substrate and the 
cofactor pyridoxal 5'-phosphate among bacterial diaminopimelate decarboxylases, 
eukaryotic ornithine decarboxylases and arginine decarboxylases  
This study represents the diaminopimelate decarboxylase LysA, which converts 
meso-diaminopimelate into lysine and is the last step of the DAP lysine biosyntheti c 
pathway. 
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Fig 05- Lysine Biosynthetic Pathway 
The Mycobacterium tuberculosis lysA gene encodes the enzyme meso-
diaminopimelate decarboxylase (DAPDC), a pyridoxal-5_-phosphate (PLP)-dependent 
enzyme. The enzyme catalyzes the final step in the lysine biosynthetic pathway 
converting meso-diaminopimelic acid (DAP) to L-lysine. 
meso-2,6-diaminoheptanedioate  L-lysine + CO2 
The lysA gene of M. tuberculosis H37Rv has been established as essential for 
bacterial survival in immunocompromised mice, demonstrating that de novo 
biosynthesis of lysine is essential for in vivo viability. Drugs targeted against DAPDC 
could be efficient anti-tuberculosis drugs, and the three-dimensional structure of 
DAPDC from M. tuberculosis complexed with reaction product lysine and the ternary 
complex with PLP and lysine in the active site has been determined.
 [11] [12]  
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CRYSTAL STRUCTURE OF DIAMINOPIMELATE DECARBOXYLASE
  
 
The crystal structure of M. tuberculosis DAPDC confirms its classification as a 
fold type III B6 dependent enzyme. DAPDC has a fold similar to eukaryotic ODCs (14 –
16), and DAPDC also forms a stable head-to-tail homodimer of practically identical 
subunits. Each of the DAPDC subunits (related by proper 2-fold rotation) consists of 
two ODC-like domains. Domain I is composed of residues 48–308 forming a barrel 
comprised of α/β barrels comprised of β strands (β4–β13) and helices (α2–α10). The 
first 47 residues are located in domain II and contain strands , and helix α1, leading into 
helix α2 of the barrel. The C-terminal domain II contains residues 2–47 (β1, β2, β3, and 
α1) and 309– 446 (α11–α13, strands β14–β21) and forms a mixed -sheet flanked by β 
helices. The two structural domains are connected by helix α2 and β13. All of the loops 
connecting the β strands and α helices were clearly visible in the electron density. Two 
identical binding sites are formed by residues of both polypeptide chains of the dimer.  
The active site is at the interface between the α/β barrel domain of one subunit 
and the sheet domain of both subunits. Residues from the α/β barrel are mainly involved 
in binding PLP, whereas residues from the sheet domain primarily contribu te to 
substrate binding. Large conformational changes between the binary DAPDC -lysine and 
ternary DAPDC-PLP-lysine complex are absent. The only significant differences 
between the DAPDC complex structures appear near the substrate and cofactor binding 
sites.
 [13] 
 
Fig 06-Overview of the M. tuberculosis DAPDC structure. 
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The PLP-binding Site—The active site of M. tuberculosis DAPDC is located in a 
shallow, highly hydrophilic cavity between the dimer interfaces with the deep PLP 
binding pocket located near the C-terminal ends of the β strands of the α/β barrel, 
similar to other ODCs.  
The oxygen atoms of the PLP phosphate group hydrogen bond with the peptide 
backbone nitrogen atoms of Gly-258 in the glycine rich motif and those of Gly-302 and 
Arg-303. OP1 also forms a hydrogen bond with the hydroxyl group of Tyr-405. In the 
DAPDC-lysine binary complex, a sulfate ion occupies the same position as the 
phosphate group of PLP in the ternary DAPDC-PLP-lysine structure. 
In addition to the covalent link to Lys-72, the pyridyl moiety of PLP is 
positioned by a hydrogen bond to the side chain carboxylate of Glu-300, which 
participates in an extended hydrogen bond network with Asp-91 and the conserved 
residues Asp-254 and His-211. 
Lysine Binding to M. tuberculosis DAPDC—In the DAPDC PLP-lysine 
complex, the density for reaction product lysine could be located in each binding site. 
In binding site B, the density is very clear and allowed unambiguous positioning and 
refinement of the lysine molecule. In site A, the lysine is again oriented similarly to the 
first site, but its exact position along the channel opening in the binding site is not as 
clear as for site B. Both lysines are positioned with the side chain toward the si face of 
the PLP pyridyl ring, consistent with decarboxylation occurring on this side of the ring.  
The carboxyl group of lysine is further fixed by conserved residue Arg-303, 
which participates in PLP binding via backbone N contacts as well. The ε -amino group 
and CE of lysine are positioned reasonably close to the catalytic Schiff base formed by 
the Lys-PLP internal aldimine. A model of the substrate DAP based on the bound lysine 
would thus have its (D)-aminoacyl group in a position to interact with the internal 
aldimine from the si side of the pyridoxyl ring as well as with conserved His-213, Arg-
161, and possibly Ser-377. 
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ENZYMOLOGY OF DAPDC 
GENE NAME lysA 
RV NUMBER Rv1293 
TYPE CDS 
FUNCTION 
Involved in biosynthesis of lysine (last step) [catalytic 
activity: MESO-2,6- diaminoheptanedioate = L-lysine + 
CO(2)]. 
PRODUCT Diaminopimelate decarboxylase LysA (DAP decarboxylase)  
FAMILY 
Belongs to family 2 of ornithine, DAP, and arginine 
decarboxylases. 
MOLECULAR MASS 
(Da) 47425.9 
ISOELECTRIC POINT 5.0704 
GENE LENGTH (bp) 1344 
PROTEIN LENGTH 447 
LOCATION (kb) 1448.03 
FUNCTIONAL 
CATEGORY 
Intermediary metabolism and respiration Identified in the 
cell wall fraction of M. tuberculosis H37Rv using 
2DLC/MS. Identified by mass spectrometry in Triton X-114 
extracts of M. tuberculosis 
PROTEOMICS 
H37Rv. Identified by mass spectrometry in the membrane 
protein fraction and whole cell lysates of M. tuberculosis 
H37Rv but not the culture filtrate. Essential gene by 
Himar1-based transposon mutagenesis in H37Rv strain.  
MUTATION 
Essential gene for in vitro growth of H37Rv, by sequencing 
of Himar1-based transposon mutagenesis 
PROTEIN DATA 
BANK 3C5Q 
ENZYME 
CLASSIFICATION 
4.1.1.20 
GENE ONTOLOGY 
Diaminopimelate decarboxylase activity lysine biosynthetic 
process via diaminopimelate 
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SELECTION OF DRUG TARGETS 
A biological target is a biopolymer such as a protein or nucleic acid whose 
activity can be modified by an external stimulus. The implication is that a molecule is 
"hit" by a signal and its behavior is thereby changed. Biological targets are most 
commonly proteins such as enzymes, ion channels, and receptors.  
The "target" is a naturally existing cellular or molecular structure involved in the 
pathology of interest that the drug-in-development is meant to act on.  
The most common drug targets of currently marketed drugs include  
 Proteins
o G protein-coupled receptors (target of 50% of drugs)
o Enzymes (especially protein kinases, proteases, esterases, and 
phosphatases)
 Ion channels
o Ligand-gated ion channels
o Voltage-gated ion channels
o Nuclear hormone receptors
o Structural proteins such as tubulin
o Membrane transport proteins
o Nucleic acids
"Established targets" are those for which there is a good scientific understanding, 
supported by a lengthy publication history, of both how the target functions in norm al 
physiology and how it is involved in human pathology.  
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"New targets" are all those targets that are not "established targets" but which have 
been or are the subject of drug discovery campaigns. These typically include newly 
discovered proteins, or proteins whose function has now become clear as a result of basic 
scientific research.
 [14] [15]
  
SCREENING AND DESIGN OF CHEMICAL ENTITIES:  
The process of finding a new drug against a chosen target for a particular disease 
usually involves high-throughput screening (HTS), wherein large libraries of chemicals 
are tested for their ability to modify the target.  
High-throughput screening (HTS) is a method for scientific experimentation 
especially used in drug discovery and relevant to the fields of biology and chemistry. 
Through this process one can rapidly identify active compounds, antibodies or genes which 
modulate a particular biomolecular pathway. The results of these experiments provide 
starting points for drug design and for understanding the interaction or role of a 
particular biochemical process in biology.  
Another important function of HTS is to show how selective the compounds are 
for the chosen target. The idea is to find a molecule which will interfere with only the 
chosen target, but not other, related targets. To this end, other screening runs will be 
made to see whether the "hits" against the chosen target will interfere with other related 
targets - this is the process of cross-screening. Cross-screening is important, because 
the more unrelated target a compound hits, the more likely that off- target toxicity will 
occur with that compound once it reaches the clinic.
 [16] [17]  
DRUG DISCOVERY- FROM HIT TO LEAD  
Early drug discovery involves several phases from target identification to 
preclinical development. The identification of small molecule modulators of protein 
function and the process of transforming these into high-content lead series are key 
activities in modern drug discovery. The Hit-to-Lead phase is usually the follow-up of 
high-throughput screening (HTS). It includes the following steps:  
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HIT CONFIRMATION PHASE:  
 Re-testing: compounds that were found active against the selected target are re -
tested using the same assay conditions used during the HTS. 
 Dose response curve generation: several compound concentrations are tested  
using the same assay. An IC50 or EC50 value is then generated. Methods are 
being developed that may allow the reuse of the compound that generated the hit 
in the initial HTS step. 
 Orthogonal testing: Confirmed hits are assayed using a different assay which is  
usually closer to the target physiological condition or using a different 
technology.
 Secondary screening: Confirmed hits are tested in a functional assay or in a  
cellular environment. Membrane permeability is usually a critical parameter.
 Chemical amenability: Medicinal chemists evaluate compounds according to 
their synthesis feasibility and other parameters such as up-scaling or costs
 Intellectual property evaluation: Hit compound structures are quickly checked 
in specialized databases to define patentability 
 Biophysical  testing: Nuclear  magnetic  resonance (NMR), Isothermal  Titration 
Calorimetry, dynamic light scattering, surface Plasmon resonance, dual 
polarisation interferometry, microscale thermophoresis (MST) are commonly 
used to assess whether the compound binds effectively to the target, the 
stoichiometry of binding, any associated conformational change and to identify 
promiscuous inhibitors.
 Hit ranking and clustering: Confirmed hit compounds are then ranked according 
to the various hit confirmation experiments.
 [18]

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HIT EXPANSION  
Following hit confirmation, several compound clusters are chosen  according to 
their characteristics in the previously defined tests. An ideal compound cluster will:  
 Have compound members that exhibit a high affinity towards the target (less than 
1 µM) 
 Moderate molecular weight and lipophilicity (usually measured as cLogP). 
Affinity, molecular weight and lipophilicity can be linked in single parameter 
such as ligand efficiency and lipophilic efficiency to assess druglikeness  
 Showed chemical tractability 
 Be free of Intellectual property 
 Showed not interfere with the P450 enzymes nor with the P-glycoproteins 
 Showed not bind to human serum albumin 
 Be soluble in water (above 100 µM) 
 Be stable 
 Have a good druglikeness 
 Exhibit cell membrane permeability 
 Showed significant biological activity in a cellular assay 
 Showed Not exhibit cytotoxicity 
 Showed Not be metabolized rapidly 
 Showed selectivity versus other related targets
[18]
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LEAD OPTIMIZATION PHASE  
The objective of this drug discovery phase is to synthesize lead compounds, new 
analogs with improved potency, reduced off-target activities, and 
physiochemical/metabolic properties suggestive of reasonable in vivo pharmacokinetics. 
This optimization is accomplished through chemical modification of the hit structure, with 
modifications chosen by employing knowledge of the structure-activity relationship (SAR) 
as well as structure-based design if structural information about the target is available.
 [18] 
DRUG LIKENESS  
Drug likeness is a qualitative concept used in drug design for how "druglike" a  
substance is with respect to factors like bioavailability. It is estimated from  the 
molecular structure before the substance is even synthesized and tested. A druglike 
molecule has properties such as:  
Solubility in both water and fat, as an orally administered drug needs to pass 
through the intestinal lining after it is consumed, carried in aqueous blood and penetrate 
the lipid cellular membrane to reach the inside of a cell. A model compound for the 
lipophilic cellular membrane is octanol (a lipophilic hydrocarbon), so the logarithm of 
the octanol/water partition coefficient, known as LogP, is used to predict the 
solubility of a potential oral drug. This coefficient can be experimentally measured or 
predicted computationally, in which case it is sometimes called "cLogP". 
Potency at the target of interest. High potency (high value of pIC50) is a 
desirable attribute in drug candidates, as it reduces the risk of non-specific, off-target 
pharmacology at a given concentration. When associated with low clearance, high 
potency also allows for low total dose, which lowers the risk of idiosyncratic drug 
reactions. 
Several scoring methods can be used to express druglikeness as a function of 
potency and physicochemical properties, for example ligand efficiency and lipophilic 
efficiency. 
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Since the drug is transported in aqueous media like blood and intracellular fluid, 
it has to be sufficiently water-soluble. Solubility in water can be estimated from the 
number of hydrogen bond donors vs. alkyl side chains in the molecule. Low water 
solubility translates to slow absorption and action. Too many hydrogen bond donors, on 
the other hand, lead to low fat solubility, so that the drug cannot penetrate the cell wall 
to reach the inside of the cell. 
Molecular weight: The smaller the better, because diffusion is directly affected. 
Eighty percent of traded drugs have molecular weights under 450 daltons; they belong 
to the group of small molecules. 
Substructures that have known chemical or pharmacological properties. For 
example, alkyl nitro compounds tend to be irritants.
 [19] [20] [21] 
LIPINSKI’S RULE OF FIVE  
Lipinski's rule of five also known as the Pfizer's rule of five or simply the Rule 
of five (RO5) is to evaluate druglikeness or determine if a chemical compound with a 
certain pharmacological or biological activity has properties that would make it a likely 
orally active drug in humans. The rule was formulated by Christopher A Lipinski in 
1997. 
Lipinski et al, has proposed rule of five which describes the molecular 
properties that are important for a drugs pharmacokinetics (ADME). The rule has been 
summarized below: 
 Molecular Weight less than 500 Daltons  
 Calculated log P value should be less than 5  
 Less than 10 hydrogen bond acceptor groups (e.g.: -O-, -N-, etc.)  
 Less than 5 hydrogen bond donar groups (e.g.: OH, NH, etc.)  
 Less than 10 rotatable bonds  
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The rule describes molecular properties important for a drug’s pharmacokinetics 
in the human body, including their absorption, distribution, metabolism, and excretion 
("ADME"). However, the rule does not predict if a compound is pharmacologically 
active.
 [22] [23] [24] 
PHARMACOPHORE MODELING  
Pharmacophore approaches have become one of the major tools in drug 
discovery. Various ligand-based and structure-based methods have been developed for 
improved pharmacophore modeling and have been successfully and extensively applied 
in virtual screening, de novo design and lead optimization.  
Historically, pharmacophores were established by Lemont Kier, who first 
mentions the concept in 1967. A pharmacophore is a description of molecular features 
which are necessary for molecular recognition of a ligand by a biological 
macromolecule. The IUPAC defines a pharmacophore to be "an ensemble of steric and 
electronic features that is necessary to ensure the optimal supramolecular interactions 
with a specific biological target and to trigger (or block) its biological response".  
   
Fig 07 - An example of a pharmacophore model . 
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Typical pharmacophore features include hydrophobic centroids, aromatic rings, 
hydrogen bond acceptors or donors, cations, and anions. These pharmacophoric points 
may be located on the ligand itself or may be projected points presumed to be located in 
the receptor. 
The features need to match different chemical groups with similar properties, in 
order to identify novel ligands. Ligand-receptor interactions are typically “polar 
positive”, “polar negative” or “hydrophobic”. A well -defined pharmacophore model 
includes both hydrophobic volumes and hydrogen bond vectors.
 [24] [25]  
HISTORY OF CHEMOTHERAPY OF TUBERCULOSIS  
The present chemotherapy treatment for tuberculosis is one of the most spectacular 
achievements of medicine. Since 50 years ago, when the only effective treatment methods 
were surgically collapsing the lung and sanatoriums, we have advanced to a very different 
treatment of drug regimens which are easy to use, have low toxicity, and are effective in 
every case. The main goal in  treating Tuberculosis was to avoid hindering natural cures. 
Continual rest, a balanced diet, and abstaining from anything in excess including sex were 
considered crucial. A well-balanced diet and drinking a large amount of milk from a cow, 
goat, or woman by itself or mixed with honey, were also important. For centuries, milk was 
practically considered the cure for tuberculosis.  
During the 16th and 17th centuries, sulfur, arsenic, mercury, and every type of 
plant from the New World such as quinine (tea), cocoa, and tobacco were all thoroughly 
tested and none were found to be useful.  
An interesting therapy called “cure by regal touch” was started in the middle 
Ages and persisted until the 19th century. This privilege given to some kings 
(especially French and English) was to cure certain illnesses by placing their hands over 
the patient while reciting the phrase “the king touches you and God cures you.”  
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In 1920, a microbiologist, A. Calmette, and his veterinarian student, C. Guerin, 
spent three years cultivating bacteria and eventually found a bovine species of bacteria 
with rare virulence that could possibly be developed into active immunity against 
tuberculosis. 
The BCG vaccine was a great hope to many but because of its widespread use, 
actually became an obstacle for the powerful impact of modern chemotherapy 
A few years after the discovery of penicillin, Selman A. Waksman demonstrated 
that small fungi of the genus Streptomyces griseus inhibit the growth of M.tuberculosis 
cultures because of a substance called Streptomycin. The massive industrial production 
of streptomycin in 1946 produced the first effective chemotherapy against tuberculosis.  
J. Lehman synthesised para-amino-salicylic acid in 1944 and later discovered 
isonaizid, a hydrazine from isonicotinic acid. Administration of isonaizid with 
streptomycin solved the problem of resistance and finally achieved the long-lived dream 
of mankind: to find a chemotherapy treatment to cure all the cases and visceral regions 
of tuberculosis. Despite its advantages, a serious inconvenience to the effectiveness of 
the treatment was the need to administer the drugs for 12-18 months to ensure 
sterilization. 
In 1966, the Italian Pietro Sensi isolated Rifamycin S from fungus of the genus  
Streptomyces mediterranii. It was supposedly a new treatment revolution to be verified 
upon experimental studies because its actions against all types of bacteria 
complimented the specific activity of pyrazinamide against intercellular bacteria. These 
findings were the basis of shortened chemotherapy treatment of 6 months. They were 
tested in a clinical study in east Africa between 1972 and 1976 and were recommended 
as initial treatment for tuberculosis.
 [26]  
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History of Tuberculosis Drug Discovery 
THE NEED FOR NOVEL TUBERCULOSIS DRUGS 
[27] [28] [29] 
 To improve current treatment by shortening the total duration of treatment.  
 To provide more effective treatment of latent tuberculosis infection.  
 New drugs to improve current drugs that facilitate compliance by providing less 
intensive supervision are also of great interest.  
 Discovery of a compound that would reduce both the total length of treatment 
and the frequency of drug administration.  
 Emergence of MDR Tb, XDR Tb and TDR Tb needs to be attended to with never 
molecules. 
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2. AIM AND OBJECTIVE OF THE STUDY 
AIM 
 The aim is to design and synthesis never antitubercular agents which will 
be more potent and possess less side effects and effective against resistant form 
of Tb. 
OBJECTIVE 
The present study relates to the synthesis of various pyridine-4-carbohydrazide 
and pyridine-3-carbohydrazide derivatives and subsequent screening for their anti-
tubercular activity. Due to several toxic effects of isoniazid, attempts were made to 
eliminate the toxicophore and substituting with a group contributing to the anti -
tubercular action. This work also aims the same motive and the compounds were 
synthesized according to the developed and valid synthetic route.  
The plan of work includes: Design of DiAminoPimelate DeCarboxylase 
(DAPDC)  inhibitors by docking studies using Argus lab 4.0 software.  
The present study carried out based on the following design.  
Identification of the lead compound 
 
Lead optimization 
 
Docking of the molecule to the target protein 
 
Top docking score compounds selected 
 
IN-SILICO  drug likeness  and toxicity risk prediction 
 
Synthesis 
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 
Justification of purity-TLC, MP,GC 
 
Characterization – Spectroscopy (IR, NMR,GC-MS and LC-MS) 
 
IN-VITRO  anti-tubercular activity 
                
              Results and Discussion      
                              
   Summary and Conclusion 
 
DOCKING 
Several chemical libraries containing various scaffolds will be sketched and 
docked against the 3D structure of DAPDC. The compounds for the synthesis were 
chosen based on the high G-Score and their feasibility in synthetic chemistry.  
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3. REVIEW  OF LITERATURE 
The purpose of a literature review is to:  
 Establish a theoretical framework for a topic / subject area  
 Define key terms, definitions and terminology 
 Identify studies, models, case studies etc supporting a topic  
 Define / establish an area of study. 
The  following  works  throw  light  upon  the  various  genomic  aspects  of 
M.tuberculosis and also various targets intended for drug action 
RELATED TO GENOMICS ASPECTS 
 Ashok  Rattan  et  al  (1998)  published  his  work  on  Multidrug-Resistant 
Mycobacterium tuberculosis: Molecular Perspectives.
 [30]

 Puneet Chopra et al (2003) reported New drug targets for Mycobacterium 
tuberculosiss.
[31]

 James C Sacchettini et al (2003) reported Mycobacterium tuberculosis: a model  
system for structural genomics.
[32]

 R. Hernandez Pando et al (2006) published their work on The use of mutant  
mycobacteria as new vaccines to prevent tuberculosis.
 [33]

 Khisimuzi Mdluli and Melvin Spigelman (2006) reported Novel targets for 
tuberculosis drug discovery.
[34]

 Johan Weigelt et al (2008) published their work correlating Structural genomics  
and drug discovery: all in the family. 
[35]
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 Yee Siew Choong (2011) reported the Effects of Enoyl-Acyl Protein Carrier 
Reductase Mutations on Physiochemical Interactions with Isoniazid: Molecular 
Dynamics Simulation.
 [36]

 .T. Cole et al (2012)  worked on Isolation and characterization of isoniazid-
resistant mutants of Mycobacterium smegmatis and M. aurum.
 [37]

 Dorothy Yeboah-Manu et al (2014) conducted a study on Drug Susceptibility 
Pattern of Mycobacterium Tuberculosis Isolates From Ghana; Correlation with 
Clinical Response.
 [38]

RELATED TO TARGETS 
 Soumya S. Ray et al (2002) worked on Co crystal Structures of Diaminopimelate 
Decarboxylase: Mechanism, Evolution, and Inhibition of an Antibiotic 
Resistance Accessory Factor.
 [39]

 Kuppan Gokulan et al (2003) reported Crystal Structure of Mycobacterium 
tuberculosis Diaminopimelate Decarboxylase, an Essential Enzyme in Bacterial  
Lysine Biosynthesis.
 [40]

 Simone Weyand et al (2009) reported The three-dimensional structure of 
diaminopimelate decarboxylase from Mycobacterium tuberculosis reveals a 
tetrameric enzyme organization.
 [41]

 Viola RE et al (2011) reported The catalytic machinery of a key enzyme in 
amino Acid biosynthesis.
 [42]

 Sakshi Kohli et al (2012) Comparative genomic and proteomic analyses of 
PE/PPE multigene family of Mycobacterium tuberculosis H37Rv and H37Ra 
reveal novel and interesting differences with implications in virulence.
 [43]

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RELATED TO SYNTHESIS 
 Jørn B. Christensen (2001) carried out a A Simple Method for Synthesis of 
Active Esters of Isonicotinic and Picolinic Acids.
 [44]

 Suriyati Mohamad et al (2004) studied the Susceptibility of Mycobacterium 
tuberculosis to isoniazid and its derivative, 1-isonicotinyl-2-nonanoyl hydrazine: 
investigation at cellular level.
 [45]

 Marcus V. N. de Souza et al (2007) Evaluation of anti-tubercular activity of 
nicotinic and isoniazid analogues.
 [46]



 Marcus Vinı´cius Nora de Souza (2008) carried out Synthesis and anti-
mycobacterial activity of (E)-N0-(monosubstituted-benzylidene) isonicotino 
hydrazide derivatives.
 [47]

 

 R.P. Tripathi (2009) worked on Design and Development of New Generation of  
Antitubercular Agents.
 [48]

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 Miyeon Jang (2009) established Synthesis and biological evaluation of bicyclic 
heterocycles.
 [49]

 Mauro V. de Almeida et al (2009) Synthesis and antitubercular activity of  
isoniazid condensed with carbohydrate derivatives.
 [50]

 Marcus V.N. de Souza et al (2010) carried out Synthesis and Antitubercular  
Activity of Heteroaromatic Isonicotinoyl and 7-Chloro-4-Quinolinyl Hydrazone 
Derivatives.
 [51]

 Roberta Cassano et al (2011) reported Synthesis, characterization and in-vitro 
antitubercular activity of isoniazid-gelatin conjugate.
 [52]
 
 
 Jahnavialuri (2011) carried out Synthesis of Certain Derivatives of Schiff bases 
of Isoniazid and Its in-Vitro Assay against Tuberculosis - Multi and Extremely 
Drug Resistance Strains.
 [53]

 Vikramjeet Judge et al (2011) worked on Isonicotinic acid hydrazide  
derivatives: synthesis, antimicrobial activity, and QSAR studies.
 [54]

 C.N.Nalini et al (2011) worked on Structure Based Drug Design, Synthesis,  
Characterization And Biological Evaluation Of Novel Isoniazid Derivatives .
 [55]
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 Anu kajal et al (2013), Schiff Bases: Schiff Bases : A Versatile 
Pharmacophore.
[56] 
  
 Ruchi Agarwal et al (2013), Schiff base complexes derived from 
thiosemicarbazone, synthesis characterization and their biological activity .
 [57]
 
RELATED TO MICROPLATE ALAMAR BLUE ASSAY 
 Page et al (1993) conducted A New Fluorometric Assay for Cytotoxicity 
Measurements InVitro.
 [58]

 Geier, Steven (1994) published his work on Analysis of alamar Blue Overlap:  
Contribution of Oxidized to Reduced.
 [59]

 Lancaster, M.V. and Fields, R.D. (1996)  carried out Antibiotic and Cytotoxic 
Drug Susceptibility Assays using Resazurin and Poising Agents.
 [60]

 R Hamid et al (2004) carried out Comparison of alamar blue and MTT assays for  
high through-put screening.
 [61]

 C. N. Paramasivan et al (2004) carried out Evaluation of microplate Alamar 
blue assay for drug susceptibility testing of Mycobacterium avium complex 
isolates.
 [62]

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4. MATERIALS AND METHODOLOGY           
          REACTANT PROFILE 
ISONIAZID 
N
NHO
NH2
 
Molecular Formula : C6H7N3O 
Molecular Weight : 137.13 g/Mol 
Description : White Crystalline solid 
Melting point : 169°C-174°C 
Solubility : Soluble in water, methanol, ethanol 
NICOTINIC ACID HYDRAZIDE 
N
NHO
NH2
 
Molecular Formula : C6H7N3O 
Molecular Weight : 137.13 g/Mol 
Description : White Crystalline solid 
Melting point : 160°C-163°C 
Solubility : Soluble in water, methanol, ethanol 
PYRIDINE -2-METHOXY-5-CARBOXALDEHYDE 
N O
O
CH3
 
Molecular 
Formula : C7H7NO2 
Molecular Weight : 137.13 g/Mol 
Description : 
Off  White to light yellow Crystalline 
powder 
Melting point : 51°C-54°C 
Solubility : 
Soluble in methanol,ethanol. Insoluble 
in water 
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4-BENZYLOXY BENZALDEHYDE 
O
O
 
Molecular 
Formula : C14H12O2 
Molecular 
Weight : 212.24 g/Mol 
Description : 
Creamish to Yellow Crystalline 
Powder 
Melting point : 71°C-74°C 
Solubility : 
Soluble in methanol, ethanol. 
Insoluble in water 
3,4 DICHLORO BENZALDEHYDE 
O
Cl
Cl 
Molecular Formula : C7H4Cl2O 
Molecular Weight : 175.01 g/Mol 
Description : White Crystalline solid 
Melting point : 43°C-45°C 
Solubility : 
Soluble in methanol,ethanol. Insoluble in 
water 
2-METHYL INDOLE-3-CARBOXALDEHYDE 
N
H
O
CH3
 
Molecular Formula : C10H9NO 
Molecular Weight : 159.18 g/Mol 
Description : Brownish White  powder 
Melting point : 204°C-205°C 
Solubility : Soluble in water, methanol, ethanol 
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3,4,5 TRIMETHOXY BENZALDEHYDE 
O
O
O
O
CH3
CH3
CH3  
Molecular 
Formula : C10H12O4 
Molecular 
Weight : 196.19 g/Mol 
Description : Light Yellowish solid 
Melting point : 73°C-75°C 
Solubility : 
Soluble in methanol,ethanol. Slightly 
soluble in water. 
P-HYDROXY BENZALDEHYDE 
O
OH 
Molecular Formula : C7H6O2 
Molecular Weight : 122.12 g/Mol 
Description : Yellowish powder 
Melting point : 112°C-116°C 
Solubility : Soluble in water, methanol, ethanol 
BENZOYL CHLORIDE 
Cl
O
 
Molecular Formula : C7H5ClO 
Molecular Weight : 140.56 g/Mol 
Description : Colorless Fuming liquid  
Melting point : 197.2°C 
Solubility : 
Soluble in organic liquids, reacts with 
water 
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Docking program is used to fit the ligand molecules into the target structure in a 
variety of positions, conformations, and orientations. Docking mode is known as pose. 
Each pose is scored based on its complementarity to the target in terms of shape and 
properties such as electrostatics in order to identify the most favorable energetical pose.  
The quality of any docking result depends on the starting structure of both the 
protein and the potential ligand. The protein and ligand structures need to be prepared 
to achieve the best docking results.
 [63]  
MOLECULAR DOCKING BY ARGUS LAB 4.0  
Argus lab 4.0 is distributed freely for windows platforms by planaria software. 
It is an introductory molecular modeling package with academics.  Argus lab 
approximates an exhaustive search method which is similar to DOCK and GLIDE. 
Flexible ligand docking is possible with Argus lab, where the ligand is described as 
torsion tree or free and grids are constructed that overlay the binding site. The a ccuracy 
of the Argus lab docking algorithm takes into account, the key features such as the 
nature of the binding site and the number of rotatable bonds to the ligand.
 [64]  
MOLEGRO
®
 MOLECULAR VIEWER 
Molegro
®
 molecular viewer is an application which helps in analyzing the 
energies and interaction of the binding site.  
Q-site finder 
Q-site finder is an energy-based method for protein-ligand binding site 
prediction. During prediction we use the crystal structures  of macromolecules (receptor) 
with small substrates (pdb ID). Identifying the location of binding sites on a protein is 
of fundamental importance for a range of applications including molecular docking. It 
uses the interaction energy between the protein and a simple vanderwaals probe to 
locate energetically favourable binding sites.
 [65] 
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STEPS INVOLVED IN DOCKING PROCEDURES 
A.PREPARATION OF PROTEIN 
B.IDENTIFICATION/ SELECTION OF ACTIVE SITE 
C.PREPARATION OF LIGANDS 
D.DOCKING PARAMETER 
E.VISUALIZATION/INTERPRETATION OF DOCKING 
A.PREPARATION OF PROTEIN 
Enter protein pdb ID (3C5Q) in the protein data bank and downloaded the protein 
pdb ID as a text file and saved to the desktop. Then opened Argus Lab file imported 
pdb file from the desktop. 3D structure of the protein appeared in the workspace of 
Argus Lab.Later opened the pdb ID, residues and miscellaneous. From miscellaneous 
deleted the inhibitors and hetero residues, but not deleted cofactor. Afterwords all the 
water molecules were deleted and added hydrogen atoms. Later opted energy by 
Universal Force Field (UFF) method and started the calculation. The prepared protein 
saved as *.agl file format in the desktop.  
B.IDENTIFICATION/ SELECTION OF ACTIVE SITE  
Open Q-site finder opened through online, imported the pdb format of the protein 
and selected all the active amino acids site from the list of amino acids. The selected 
amino acids residues were grouped as in the name of ‘Binding Site’  
C.PREPARATION OF LIGAND  
The ligand drawn in Chem sketch and saved it as MDL mol file format and it 
imported into the workspace of the Argus Lab. The ligand were prepared by cleaning 
the geometry and hybridization, then it grouped as in the name of ‘Ligand’   Import the 
ligand into workspace of Argus lab.  
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D.DOCKING PARAMETER 
From the calculation of the tool bar ‘Argus Dock’ selected as the  Docking engine. 
Dock were selected as calculation type and ‘Flexible’ for the ligand. Then started the 
docking and the docked. Docked protein ligand compex saved as Brookhaven pdb files 
(*.pdb).  
E.VISUALIZATION/INTERPRETATION OF DOCKING  
Molegro molecular viewer will help in analyzing The energies and interaction of 
the Protein-Ligand binding viewed and analysed by Molegro
®
 Molecular Viewer.
 
SCORING FUNCTION 
These are mathematical methods used to predict the strength of the non-covalent 
interaction called as binding affinity, between the two molecules after they have been 
docked. Scoring functions have also been developed to predict the strength of other 
types of intermolecular interactions, for sample between two proteins or between 
protein and DNA or protein and drug. These configurations are evaluated using scoring 
functions to distinguish the experimental binding modes from all other modes explored 
through the searching algorithm.
 [66] 
PREDICTION OF ADME 
ADME acronym is used to indicate phenomenon associated with Absorption, 
Distribution, Metabolism and Elimination. Therefore, a full consideration of molecular 
structure and their impact on ADME profile will enable the chemists to elimina te 
negative ADME attributes (e.g. chemically active moiety) and incorporate desirable 
ADME attributes (e.g. optimal log P, good membrane permeability, etc.). Hence the 
prediction is crucial to the drug development process. In recent years, many insilico 
tools are available to determine those properties.
 [67] 
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INSILICO SCREENING OF DRUG LIKENESS  
The designed and docked molecules are screened insilico using Molinspiration 
cheminformatics software to evaluate drug likeness. Molinspiration supports internet 
chemistry community by offering free on-line services for calculation of important 
molecular properties such as logP, polar surface area, number of hydrogen bond donors 
and acceptors and others, as well as prediction of bioactivity score for the most 
important drug targets like GPCR ligands, kinase inhibitors, ion channel modulators, 
nuclear receptors. 
INSILICO TOXICITY PREDICTION  
Toxicity is one of the major criteria to be considered for a molecule to shine as a 
successful clinical candidate in pharmaceutical research. About 20-40% of drug failure 
comes under this category. Commercial insilico tools estimates toxicity and provides 
information by the use of QSAR, scientific literatures and to some extent in abstracting 
issues from humans. 
[68]
 
Toxicity screening is done insilico using OSIRIS Property Explorer. The 
OSIRIS Property Explorer lets us to draw chemical structures and calculates on-the-fly 
various drug-relevant properties whenever a structure is valid. Prediction results are 
valued and color coded. Properties with high risks of undesired effects like 
mutagenicity or a poor intestinal absorption are shown in red. Whereas a green color 
indicates drug-conform behavior.
[69] [70] 
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SYNTHETIC METHODOLOGY 
                                                                                                   
DRUG PROFILE 
SCHIFF BASE 
Schiff bases are the compounds carrying imine or azomethine (–C=N–) 
functional group. These are the condensation products of primary amines with carbonyl 
compounds and were first reported by Hugo Schiff. Schiff bases form an important 
class of the most widely used organic compounds and has a wide variety of applications 
in many fields including analytical, biological, and inorganic chemistry. Schiff bases 
have gained importance in medicinal and pharmaceutical fields due to a broad spectrum 
of biological activities like anti-inflammatory analgesic, antimicrobial, anticonvulsant, 
anti tubercular, anticancer, antioxidant, anthelmintic, and so forth. The nitrogen atom of 
azomethine may be involved in the formation of a hydrogen bond with the active 
centers of cell constituents and Interferes in normal cell processes. Apart from 
biological activities, Schiff bases are also used as catalysts,  intermediates in organic 
synthesis, dyes, pigments, polymer stabilizers, and Corrosion inhibitors. Schiff base 
derivatives in various processes promoted the researchers for designing of novel 
heterocyclic/aryl Schiff bases for development of new environmental friendly 
technology.
[71]
 
O
R
1
R
+ NH2 R
2 N
R
2
R
R
1
+ H2O
 
MECHANISM 
Schiff base formation involves nucleophilic addition to the carbonyl group. In 
this case, the nucleophile is the amine. In the first part of the mechanism, the amine 
reacts with the aldehyde or ketone to give an unstable addition compound called 
carbinolamine. The carbinolamine loses water by either acid or base catalyzed 
pathways. Since the carbinolamine is an alcohol, it undergoes acid catalyzed 
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dehydration. Typically the dehydration of the carbinolamine is the rate-determining step 
of Schiff base formation and that is why the reaction is catalyzed by acids.  
The Schiff base formation is really a sequence of two types of reactions, i.e. 
addition followed by elimination 
[72]
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PROCEDURE: Synthesis of Schiff bases 
[73]
 
SCHEME I 
The Compound of Schiff base was synthesized by refluxing ethanolic solution of 
Acid hydrazide (1mMol) with Aromatic/ Hetero aromatic aldehyde (R) (1mMol) in 
ethanol for 6-9 hrs. The refluxed mixture was poured in crushed ice and stirred well, 
The precipitate was filtered, dried and recrystallised from hot ethanol to yield a crystal 
form of Schiff base. 
NHO
NH2
+
O
NHO
N
Ethanol
Reflux, 6 - 9 hrs
A R
Product
 
Acid hydrazides (A) used:  
 Isonicotinic acid hydrazide (INH),  
 Nicotinic acid hydrazide (NH) 
 
Aldehydes(R)used:  
 Pyridine-2-methoxy-5-carboxaldehyde 
 4-Benzyloxy Benzaldehyde 
 3,4 Dichloro benzaldehyde 
 2-Methyl indole-3- carboxaldehyde 
 3,4,5-Trimethoxy benzaldehyde 
 P-Hydroxy benzaldehyde 
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SCHEME-II 
SYNTHESIS  OF  N-benzoyl-N'-[(E)-(6-methoxypyridin-3- yl)methylidene] pyridine-3-
carbohydrazide (RK 2a) 
STEP: 1 
The Compound of Schiff base was synthesized by refluxing ethanolic solution of 
nicotinic acid hydrazide  (1mMol) with  Aromatic/ Hetero aromatic aldehyde (R) 
(1mMol) in ethanol for 6-9 hrs. The refluxed mixture was poured in crushed ice and 
stirred well, The precipitate was filtered, dried and recrystallised from hot ethanol to 
yield a crystal form of Schiff base. 
STEP: 2 
About 1 mMol of schiff base was suspended in 20 mL of dichloromethane and 
was stirred mechanically. To this, was added 1 mMol of benzoyl chloride dropwise for 
over 15 mins and the stirring was continued for 4 - 6 hrs. The reaction mixture was 
subjected to TLC to ensure the progress of the reaction. After 4 - 6 hrs, the stirring was 
stopped and the solvent was allowed to evaporate. The solid mass was recrystallised 
from ethanol:dioxane (1:1) to yield pale yellow crystals.  
SYNTHETIC ROUTE FOR SCHEME II 
SYNTHESIS  OF  N-benzoyl-N'-[(E)-(6-methoxypyridin-3- yl)methylidene] 
pyridine-3-carbohydrazide (RK 2a) 
STEP: 1 
N
NHO
NH2
+
N
O
O
CH3
N
NHO
N
N O
CH3
Ethanol
Reflux, 6 - 9 hrs
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STEP: 2 
+
O
Cl
N
NHO
N
N O
CH3 N
NO
N
N
O
O
CH3
DCM, 20 ML
Stirring, 4 - 6 hrs
 
                    RK 2a 
 
                                  
JUSTIFICATION OF PURITY   
MELTING POINT 
The melting point of the synthesized compound was determined by one end open 
capillary method. The melting points were sharp and were presented corrected. 
THIN LAYER CHROMATOGRAPHY 
Precoated aluminium TLC plates were used. Solutions of the reactants and 
products were prepared by dissolving them in methanol.  
Stationary Phase : Precoated Silica Gel Plates 
Mobile Phase : Chloroform:Acetone:Methanol (8:1:1) 
Visualization : Iodine Vapors and UV chamber 
A single spot not corresponding to the parent compound was noticed and hence 
the purity of the synthesized compounds was justified.  
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CHARACTERIZATION  
IR SPECTROSCOPY 
Infrared (IR) spectroscopy is one of the most common spectroscopic techniques 
used by organic chemists. The main goal IR spectroscopic analysis is to determine the 
chemical functional groups in the sample. Different functional groups absorb 
characteristic frequencies of IR radiation. IR spectroscopy is an important and popular 
tool for structural elucidation and compound identification.  
The synthesized compounds were made into pellets with potassium bromide by 
pressed pellet technique using pellet press (model No: M15). The pellet was mounted 
on the pellet disc and percentage transmittance was recorded in ABB IR 
Spectrophotometer (Model No: MB 3000).  
NMR SPECTROSCOPY 
Proton NMR Spectroscopy helps us to study the number of equivalent protons 
and their environment thereby we can ascertain the structure of the molecule. The NMR 
spectra were recorded on 300 MHz BRUKER Advance III NMR Spectrometer. DMSO 
was used as solvent. 
GAS CHROMATOGRAPHY-MASS SPECTROMETRY 
Gas chromatography-mass spectrometry (GC-MS) is a hyphenated technique; 
consisting of two analytical procedures in sequence, namely a Gas Chromatography 
(GC) separation followed by Mass Spectroscopy (MS) detection. The purpose of the GC 
step is to separate multiple compounds in a sample so that they reach the MS detector 
one at the time. 
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Mass spectrometry is an analytic technique that utilizes the degree of deflection 
of charged particles by a magnetic field to find the relative masses of molecular ions 
and fragments. Mass spectrometry has a number of applications in organic chemistry,  
they are:  
1. Determining molecular mass  
2 Finding out the structure of unknown substances  
 3. Verifying the identity and purity of a known substance   Providing data on 
isotopic abundance  
 4. The mass spectra of the synthesized compounds were recorded  in Q-Tof-
Mass Spectroscopy (Q-Tof micro hybrid quadrupole time of flight mass 
spectrometer).
 [74] [75] 
                                                         Materials and Methodology 
 
Department of Pharmaceutical Chemistry, COP, MMC. Page 46 
 
MICROBIOLOGICAL ASSAY 
Microbial assays or microbiological assays is a type of bioassay and are 
designed to analyse the compounds or substances which have effect on micro-
organisms. 
Microbiological assay is defined as the determination or estimation of 
concentration or potency of an antibiotic by means of measuring and comparing the  
area of zone of inhibition or turbidity produced by test substance with that of standard 
over a suitable microbe under standard conditions. 
So as definition says the hypothesis is that when an antibiotic is administered, 
there is inhibition in the growth of microbe as indicated by decrease in area of zone of 
microbial colony on nutrition media or decrease in turbidity due to decrease in 
microbial concentration.  
Uses of microbial assay:  
 They help to estimate concentration and potency of antibiotics. This is not 
always possible by other means of estimations.  
 Help in determination of the best anti-biotic suitable for patient recovery. When 
microbe in patients phlegm or urine is examined by biosaay, the better 
susceptibility of microbe to the suitable anti-biotic among those available to treat 
can be decided for proper treatment of infected patient. This determination is 
possible by immune assays like ELISA test for some diseases.
 [76] [77] [78]
 
alamarBlue® ASSAY FOR ESTIMATING THE MICROBIAL 
VIABILITY
[79] 
Introduction 
alamarBlue® is designed to provide a rapid and sensitive measure of cell 
proliferation and cytotoxicity in various human and animal cell lines, bacteria and 
fungi. It is simple to use as the indicator dye is water soluble, thus eliminating the 
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washing/fixing and extraction steps required in other commonly used cell proliferation 
assays. 
The assay incorporates a specially selected oxidation-reduction (REDOX) 
indicator that both fluoresces and undergoes colorimetric change in response to cellular 
metabolic reduction. This offers the user a choice of detection method.  
alamarBlue® reagent contains Resazurin (7-Hydroxy-3H-phenoxazin-3-one 10-
oxide) a blue dye, which itself is non fluorescent until it is reduced to the pink colored 
and highly red fluorescent resorufin. It is used mainly as anoxidation-reduction 
indicator in cell viability  assays for  bacteria  and mammalian ce lls.  Usually  it  is  
available commercially as the sodium salt.  
 
Fig 08- alamarBlue Reagent 
ASSAY PROTOCOL FOR ESTIMATING ANTI-TB ACTIVITY USING 
alamarBlue® DYE 
1) The anti mycobacterial activity of compounds were assessed against M. 
tuberculosis using alamarBlue® micro plate assay (MABA). 
2) This methodology is non-toxic, uses a thermally stable reagent and shows good 
correlation with proportional and BACTEC radiometric method.  
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3) Briefly, 200µl of sterile deionzed water was added to all outer perimeter wells  of 
sterile 96 wells plate to minimized evaporation of medium in the test wells 
during incubation. 
4) The 96 wells plate received 100 µl of the Middlebrook 7H9 broth and serial 
dilution of compounds were made directly on plate.  
5) The final drug concentrations tested were 100 to 0.2 µg/ml. 
6) Plates were covered and sealed with paraffin and incubated at 37ºC for five days.  
7) After this time, 25µl of freshly prepared 1:1 mixture of alamarBlue® reagent and 
10% tween 80 was added to the plate and incubated for 24 hrs.  
8) A blue color in the well was interpreted as no bacterial growth, and pink color 
was scored as growth. 
9) The MIC was defined as lowest drug concentration which prevented the color 
change from blue to pink. 
FEATURES AND BENEFITS  
FEATURES 
 Fluorescent/colorimetric reaction 
 Water soluble 
 Works on suspended or attached cell lines 
 Fewer steps than traditional assays 
 Easily adaptable to automation 
 Stable 
 Non-cytotoxic 
 Non-radioactive 
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BENEFITS 
 Allows choice of detection method 
 No extraction required 
 No centrifugation required 
 Time saving 
 Useful for high throughput testing 
 Allows for continuous cell growth monitoring and kinetic studies over 
several days 
 Minimal interference with 
 Normal metabolism 
 Safe and easily disposable 
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5. RESULTS AND DISCUSSION   
RESULTS OF DRUG DESIGN 
To predict the possible binding modes and enzyme inhibition 
mechanism, compounds were docked onto the active sites of DAPDC (LysA), 
using Argus Lab software 4.0. The best pose was selected based on good G - 
Score and the favorable interactions formed between the compound and amino 
acid residues of the LysA active site. All the ligands in the complex structures 
showed the hydrogen bond interactions with LYS 407, SER 49, SER 361,  
ARG 135, TYR 302. This clearly indicates that these hydrogen bonded amino 
acids play a crucial role in LysA inhibition activity.  
A. DRUG LIKENESS 
Drug likeness is a qualitative concept used in drug design for how 
"druglike" a substance is with respect to factors like bioavailability. It is 
estimated from the molecular structure before the substance is even 
synthesized and tested. A druglike molecule has properties such as: 
hydrophobicity, electronic distribution, hydrogen bonding characteristics, 
molecule size and flexibility and course presence of various pharmacophoric 
features influence the the behavior of molecule in a living organism, 
including bioavailability, transport properties, affinity to proteins, react ivity, 
toxicity, metabolic stability and many others.  
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INSILICO DRUG LIKENESS PREDICTION 
  RK1 
 
 RK2 
 
  RK2a 
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 RK3 
 
 RK4 
 
 RK5 
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 RK6 
 
 RK7 
 
 RK8 
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 RK9 
 
INSILICO DRUG BIOACTIVITY PREDICTION 
Prediction of bioactivity score for the most important drug targets like 
GPCR ligands, kinase inhibitors, ion channel modulators, nuclear receptors.  
  RK1 
 
   
 
 
 
                                                      Results and Discussion  
 
Department of Pharmaceutical Chemistry, COP, MMC Page 55 
 
RK2 
 
  RK2a 
 
RK3 
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RK4 
 
RK5 
 
RK6 
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RK7 
 
RK8 
 
RK9 
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RESULTS OF DOCKING REPORTS 
The designed molecules were docked against the selected target 
Diaminopimelate decarboxylase (LysA) extra precision mode. Molecular 
docking was executed for perfect docking of the ligand into the cavity of the 
protein having active site .During the docking procedure different poses of 
the ligand were generated and the ligands were docked in different poses .The 
best docked poses were selected based on the energy generated and the 
interactions between the protein and the ligand. There were hydrogen bond 
interactions between all the ten molecules and the active si te. Hydrophobic 
interactions were also observed. 
DOCKING SCORE OF THE COMPOUNDS 
  
RK 1-Score:-7.14184 Kcal/Mol RK 2-Score:-6.0990 Kcal/Mol 
  
 RK 2a-Score:-7.01767 Kcal/Mol RK 3-Score:-7.02594 Kcal/Mol 
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RK 4-Score:-7.00587 Kcal/Mol RK 5-Score:-8.86707 Kcal/Mol 
  
 RK 6-Score:-7.93265 Kcal/Mol RK 7-Score:-8.32154 Kcal/Mol 
  
 RK 8-Score:-9.43975 Kcal/Mol RK 9-Score:-8.13855 Kcal/Mol 
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LIGAND INTERACTION REPORTS 
  
RK1 RK2 
  
RK2a RK3 
  
RK4 RK5 
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RK6 RK7 
  
RK8 RK9 
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The designed molecules were also  docked against  some other targets 
of Mycobacterium Tuberculosis such as 
1) Alpha 1,4-N- Acetyl glycosaminyl transferase (PDB ID- 4EEG) - 
Arginine biosynthesis for regulates cell wall and cell processes.  
2) D-3 Phosphoglycerate dehydrogenase  (PDB ID- 1YGY) – 6-Serine 
biosynthesis for cell signaling.  
3) Pyridoxamine 5-phosphate oxidase (PDB ID-5BNC) – Pyridoxine 
synthesis for intermediatory metabolism and respiration.  
4) D-Alanyl  D-Alanine Carboxypeptidase (PDB ID- 4MPH) –  
Peptidoglycan synthesis for cell wall and cell processes. 
The synthesised compounds were docked with above targets showed a 
good G-Score and Good ligant- interaction docked with  as same as the 
DAPDC.   
                                                      Results and Discussion  
 
Department of Pharmaceutical Chemistry, COP, MMC Page 63 
 
1. Docking reports and ligant interaction of syntesised copounds  
with Alpha 1,4-N- Acetyl glycosaminyl transferase   
  
RK 1-Score:-7.49361 Kcal/Mol 
  
RK 2-Score:-8.35999 Kcal/Mol 
  
RK 2a-Score: -7.83187 Kcal/Mol 
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RK 3-Score:-7.94069 Kcal/Mol 
  
RK 4-Score:-10.0529 Kcal/Mol 
  
RK 5-Score:- 8.39666 Kcal/Mol 
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RK 6-Score:-10.033 Kcal/Mol 
  
RK 7-Score:-8.25567 Kcal/Mol 
  
RK 8-Score:-10.2366 Kcal/Mol 
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RK 9-Score:-8.00789 Kcal/Mol 
2. Docking reports and ligant interaction of syntesised copounds  
with D-3 Phosphoglycerate dehydrogenase   
  
RK 1-Score:-7.1908 Kcal/Mol 
 
 
RK 2-Score:-7.67436 Kcal/Mol 
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RK 2a-Score:-7.67294 Kcal/Mol 
  
RK 3-Score:-6.55715 Kcal/Mol 
  
RK 4-Score:-11.1077 Kcal/Mol 
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RK 5-Score:-10.7417 Kcal/Mol 
  
RK 6-Score:-11.4436 Kcal/Mol 
  
RK 7-Score:-8.6646 Kcal/Mol 
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RK 8-Score:-10.5885 Kcal/Mol 
  
RK 9-Score:-8.63668 Kcal/Mol 
3. Docking reports and ligant interaction of syntesised copounds  
with Pyridoxamine 5-Phosphate oxidase 
  
RK 1-Score:-8.03589 Kcal/Mol 
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RK 2-Score:-8.23237 Kcal/Mol 
  
RK 2a-Score:-9.47464 Kcal/Mol 
  
RK 3-Score:-6.45404Kcal/Mol 
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RK 4-Score:-9.63219 Kcal/Mol 
  
RK 5-Score:-9.5003 Kcal/Mol 
  
RK 6-Score:-10.1913 Kcal/Mol 
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RK 7-Score:-9.37594 Kcal/Mol 
   
RK 8-Score:-9.60466 Kcal/Mol 
  
RK 9-Score:-8.4587 Kcal/Mol 
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4. Docking reports and ligant interaction of syntesised copounds  
with D-Alanyl D-Alanine carboxypeptidase 
  
RK 1-Score:-8.01848 Kcal/Mol 
  
RK 2-Score:-7.20556 Kcal/Mol 
  
                  RK2a-Score:-8.63945Kcal/Mol
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RK 3-Score:-7.78564 Kcal/Mol 
  
RK 4-Score:-9.6324 Kcal/Mol 
  
RK 5-Score:-8.04772 Kcal/Mol 
                                                      Results and Discussion  
 
Department of Pharmaceutical Chemistry, COP, MMC Page 75 
 
  
RK 6-Score:-9.86919 Kcal/Mol 
 
 
 
 
RK 7-Score:-8.81896 Kcal/Mol 
 
 
 
 
RK 8-Score:-9.4802 Kcal/Mol 
  
                                   RK 9-Score:-7.15868 Kcal/Mol 
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RESULTS OF SYNTHETIC SCHEME 
The compounds for the synthesis were chosen based on the high G-Score and 
their feasibility in synthetic chemistry.  The series of compounds RK1, RK2, RK2a, 
RK3, RK4, RK5, RK6, RK7, RK8 and RK9 were synthesised and its physico chemical 
properties were observed. 
  RESULTS OF CHARACTERIZATION 
The synthesised molecules were characterized by Infrared Spectroscopy, H
1
 
NMR Spectroscopy and GC-MS, LC-MS methods. 
IR  SPECTROSCOPY: 
IR Spectra mainly used  in structural elucidation to determine the various 
functional groups. Parent molecules (Primary amine and Aldehyde) shown a strectching 
vibration  -NH2 and C=O with their respective wave numbers 3500 – 3450 cm
-1
 and 
1740 – 1720 cm-1. 
 The series of synthesised products ( RK1, RK2, RK2a, RK3, RK4, RK5, RK6, 
RK7, RK8, and RK9 ) showed a C=N strectching vibration ( Ring out ) with their 
respective wave number 2360.87 cm
-1
 with also indicates the absence of parent  
molecules functional groups with their respective wave numbers (cm
-1
) which indicates 
the confirmation Schiff base formation. 
GC–MS  AND  LC-MS  SPECTROMETRY: 
GC-MS Spectra  is a hyphenated technique. Hence from the GC-MS Spectra 
given the following details of synthesised compounds.  
 Determination of molecular mass 
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 Verifying the identity and purity of the known substance providing data on 
isotopic abundance. 
LC-MS Spectra opted for characterization of the compound RK1. It were showed 
broad peak in the absorption spectra of GC-MS. The purity of the compound were same  
both in GC-MS and LC-MS.  
NMR  SPECTROSCOPY :  
NMR Spectroscopy is especially used in structural elucidation of organic 
compound. Organic compounds invariably have hydrogen atoms in their structure and 
the environment of each proton is not same. Hence from the H
1 
NMR spectra all the 
types of protons were observed from the structure. The H
1 
NMR spectra given the 
details about, 
 Types of protons 
 No of each type of protons (in δ value) 
Aromatic proton: 6.5-9.85ppm 
Aliphatic proton: 2.3-3.85ppm 
Hydroxy proton: 4.3-7.7ppm 
Methyl proton: 6-7.9ppm 
Secondary amine proton: 2-5ppm (usually broad peak) 
CH=NH type proton: 11.8-13.2ppm 
 Environment of protons (Position of the peak) 
 No of adjacent protons 
(singlet,doublet,triplet,quartet,pentatet,sextet,multiplet) 
 
The physiochemical properties profile and  characterization results of synthesised 
copounds RK1, RK2, RK2a, RK3, RK4, RK5, RK6, RK7, RK8, and RK9 were observed. 
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        REPORTS OF PRODUCT PROFILE AND CHARACTERIZATION 
1. N'-[(E)-(6-methoxypyridin-3-yl)methylidene]pyridine-4-carbohydrazide 
N
NHO
N
N O
CH3
 
     RK1                                      
  PHYSICO-CHEMICAL PROPERTIES 
Description : Light Yellowish white Crystals 
Solubility : Insoluble in water, sparingly soluble in ethanol.  
Freely soluble in methanol, DMSO 
Melting Point : 165°C 
Molecular Formula : C13H12N4O2 
Formula Weight : 256.2599 g/Mol 
Composition : C(60.93%) H(4.72%) N(21.86%) O(12.49%) 
Molar Refractivity : 71.63 ± 0.5 cm3 
Molar Volume : 206.6± 7.0 cm3 
Parachor : 543.0± 8.0 cm3 
Index of Refraction : 1.609± 0.05 
Surface Tension : 47.6 ± 7.0 dyne/cm 
Density : 1.24 ± 0.1 g/cm3 
Dielectric Constant : Not available 
Polarizability : 28.39± 0.5 10-24cm3 
Monoisotopic Mass : 256.096026 Da 
Monoisotopic Mass : 256.096026 Da 
Nominal Mass : 256 Da 
Average Mass : 256.26 Da 
M+  : 256.095477 Da 
M-  : 256.096574 Da 
[M+H]+ : 257.103302 Da 
[M+H]-  : 257.104399 Da 
[M-H]+  : 255.087652 Da 
[M-H]-  : 255.088749 Da 
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RK 1: IR SPECTRUM 
 
 N
NHO
N
N O
CH3
 
 
 
 
 
 
 
Wave number cm-1 Functional group Remarks 
3049.46, 3072.6 C-H stretching Aromatic 
1676.14 C=O stretching Amide 
3412.08 N-H stretching Amide 
1602.95 C=N stretching Aromatic (Ring in) 
2374.37 C=N stretching Aromatic (Ring out) 
2854.65 C-O-C stretching Methoxy group. 
1492.90 C=C stretching Aromatic 
 
                                                      Results and Discussion  
 
Department of Pharmaceutical Chemistry, COP, MMC Page 80 
 
RK 1: LC-MS SPECTRUM 
 
 
Actual Molecular Mass : 256.25 g/Mol 
Expected Molecular Mass: 257.12 g/Mol 
                                                      Results and Discussion  
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RK 1: H
1
 NMR SPECTRUM 
 
NO OF PROTONS TYPE OF PEAKS 
 
δ  VALUE 
 
     1 Singlet      2.55ppm 
     3 Singlet      3.85ppm 
     1 Doublet 6.75-6.85ppm 
     6 Multiplet 7.55-8.55ppm 
     1 Doublet 11.9-12ppm 
                                                      Results and Discussion  
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2.       N'-[(E)-(6-methoxypyridin-3-yl)methylidene]pyridine-3- carbohydrazide 
N
NHO
N
N O
CH3
 
       RK2 
PHYSICO-CHEMICAL PROPERTIES 
Description : Light Yellowish White Powder 
Solubility : Insoluble in water, sparingly soluble in ethanol.  
Freely soluble in methanol, DMSO 
Melting Point : 193°C 
Molecular Formula : C13H12N4O2 
Formula Weight : 256.25998 g/Mol 
Composition : C(60.93%) H(4.72%) N(21.86%) O(12.49%) 
Molar Refractivity : 71.63 ± 0.5 cm3 
Molar Volume : 206.6± 7.0 cm3 
Parachor : 543.0± 8.0 cm3 
Index of Refraction : 1.609± 0.05 
Surface Tension : 47.6 ± 7.0 dyne/cm 
Density : 1.24 ± 0.1 g/cm3 
Dielectric Constant : Not available 
Polarizability : 28.39± 0.5 10-24cm3 
Monoisotopic Mass : 256.096026 Da 
Nominal Mass : 256 Da 
Average Mass : 256.26 Da 
M+  : 256.095477 Da 
M- : 256.096574 Da 
[M+H]+  : 257.103302 Da 
[M+H]-  : 257.104399 Da 
[M-H]+  : 255.087652 Da 
[M-H]- : 255.088749 Da 
 
                                                      Results and Discussion  
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RK 2: IR SPECTRUM  
  
 
N
NHO
N
N O
CH3
 
 
 
  
 
Wave number cm-1 Functional group Remarks 
3072.60, 3014.74 C-H stretching Aromatic 
1687.71 C=O stretching Amide 
3404.36 N-H stretching Amide 
1612.49 C=N stretching Aromatic (Ring in) 
2360.87 C=N stretching Aromatic (Ring out) 
2846.93 C-O-C stretching Methoxy group. 
1498.69 C=C stretching Aromatic 
 
 
 
                                                      Results and Discussion  
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RK 2: GC-MS  SPECTRUM  
 
 
 
Actual Molecular Mass : 256.25 g/Mol 
Expected Molecular Mass: 256.48  g/Mol 
                                                      Results and Discussion  
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RK 2: H
1
 NMR SPECTRUM 
 
 NO OF PROTONS    TYPE OF PEAKS 
 
    δ  VALUE 
 
     1 Singlet       2.55ppm 
     3 Singlet       3.85ppm 
     1 Doublet   6.75-6.85ppm 
     6 Multiplet      7.5-9.3ppm 
     1 Singlet        12.2ppm 
                                                      Results and Discussion  
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3.    N-benzoyl-N'-[(E)-(6-methoxypyridin-3-  yl)methylidene]pyridine- 
 3- Carbohydrazide 
N
NO
N
N O
CH3
O
 
        RK2a 
PHYSICO-CHEMICAL PROPERTIES 
Description : Pale Yellow Gleaming solid 
Solubility : Insoluble in water, sparingly soluble in ethanol.  
Freely soluble in methanol, DMSO 
Melting Point : 88°C 
Molecular Formula : C20H16N4O3 
Formula Weight : 360.36604 g/Mol 
Composition : C(66.66%) H(4.48%) N(15.55%) O(13.32%) 
Molar Refractivity : 103.09 ± 0.5 cm3 
Molar Volume : 294.0± 7.0 cm3 
Parachor : 778.5± 8.0 cm3 
Index of Refraction : 1.618± 0.05 
Surface Tension : 49.1 ± 7.0 dyne/cm 
Density : 49.1 ± 0.1 g/cm3 
Dielectric Constant : Not available 
Polarizability : 49.1± 0.5 10-24cm3 
Monoisotopic Mass : 360.12224 Da 
Nominal Mass : 360 Da 
Average Mass  : 360.366 Da 
M+ : 360.121692 Da 
M- : 360.122789 Da 
[M+H]+  : 361.129517 Da 
[M+H]-  : 361.130614 Da 
[M-H]+  : 359.113867 Da 
[M-H]-  : 359.114964 Da 
                                                      Results and Discussion  
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RK 2a: IR SPECTRUM 
 
 
N
NO
N
N O
CH3
O
  
 
 
 
 
Wave number cm-1 Functional group Remarks 
3070.97, 3016.67 C-H stretching Aromatic 
1689.64 C=O stretching Amide 
3327.21 N-H stretching Amide 
1600.92 C=N stretching Aromatic (Ring in) 
2360.87 C=N stretching Aromatic (Ring out) 
2848.86 C-O-C stretching Methoxy group. 
1496.76 C=C stretching Aromatic 
                                                      Results and Discussion  
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RK 2a: GC-MS SPECTRUM 
 
 
 
Actual Molecular Mass : 360.36 g/Mol 
Expected Molecular Mass: 360.36 g/Mol 
                                                      Results and Discussion  
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RK 2a: H
1
 NMR SPECTRUM 
 
  NO OF PROTONS    TYPE OF PEAKS 
 
   δ  VALUE 
 
      3 Doublet    2.3-2.5ppm 
      1 Doublet    6.7-6.85ppm 
      4 Doublet    7.35-7.5ppm 
      6 Sextet    7.95-8.3ppm 
      5 Multiplet     8.7-9.9ppm 
      1 Singlet       13.2ppm 
                                                      Results and Discussion  
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4.  N'-[(E)-(3,4,5-trimethoxyphenyl)methylidene]pyridine-3-carbohydrazide 
N
NHO
N
O
O
O
CH3
CH3
CH3
 
RK3 
PHYSICO-CHEMICAL PROPERTIES 
Description : Milky White Crystals 
Solubility : Insoluble in water, sparingly soluble in ethanol.  
Freely soluble in methanol, DMSO 
Melting Point : 178°C 
Molecular Formula : C16H17N3O4 
Formula Weight : 315.32388 g/Mol 
Composition : C(60.94%) H(5.43%) N(13.33%) O(20.30%) 
Molar Refractivity : 84.81 ± 0.5 cm3 
Molar Volume : 261.4± 7.0 cm3 
Parachor : 662.4± 8.0 cm3 
Index of Refraction : 1.562± 0.05 
Surface Tension : 41.2 ± 7.0 dyne/cm 
Density : 1.20 ± 0.1 g/cm3 
Dielectric Constant : Not available 
Polarizability : 33.62± 0.5 10-24cm3 
Monoisotopic Mass : 315.121906 Da 
Nominal Mass  : 315 Da 
Average Mass  : 315.3239 Da 
M+  : 315.121357 Da 
M-  : 315.122455 Da 
[M+H]+ : 316.129182 Da 
[M+H]-  : 316.13028 Da 
[M-H]+  : 314.113532 867 Da 
[M-H]-  : 314.11463 Da 
                                                      Results and Discussion  
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RK 3: IR SPECTRUM 
 
 
N
NHO
N
O
O
O
CH3
CH3
CH3
 
 
 
 
 
 
 
Wave number cm-1 Functional group Remarks 
3184.48 C-H stretching Aromatic 
1639.48 C=O stretching Amide 
3404.36 N-H stretching Amide 
1571.99 C=N stretching Aromatic (Ring in) 
2360.87 C=N stretching Aromatic (Ring out) 
2862.36 C-O-C stretching Methoxy group. 
1421.54 C=C stretching Aromatic 
 
                                                      Results and Discussion  
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RK 3: GC – MS SPECTRUM 
 
 
Actual Molecular Mass : 315.32 g/Mol 
Expected Molecular Mass: 315.02 g/Mol 
                                                      Results and Discussion  
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RK 3: H
1
 NMR SPECTRUM 
 
 
  NO OF PROTONS    TYPE OF PEAKS 
 
    δ  VALUE 
 
    1 Singlet       2.6ppm 
    9 Singlet    3.75-3.9ppm 
   6 Multiplet     6.9-9.3ppm 
   1 Singlet       11.9ppm 
                                                      Results and Discussion  
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5. N'-{(E)-[4-(benzyloxy)phenyl]methylidene}pyridine-4-carbohydrazide 
N
NHO
N
O
 
RK4 
PHYSICO-CHEMICAL PROPERTIES 
Description : Pale Yellowish Crystals 
Solubility : Insoluble in water, sparingly soluble in ethanol.  
Freely soluble in methanol, DMSO 
Melting Point : 149°C 
Molecular Formula : C20H17N3O2 
Formula Weight : 331.36788 g/Mol 
Composition : C(72.49%) H(5.17%) N(12.68%) O(9.66%) 
Molar Refractivity : 98.47± 0.5 cm3 
Molar Volume : 286.8± 7.0 cm3 
Parachor : 746.2± 8.0 cm3 
Index of Refraction : 1.602± 0.05 
Surface Tension : 45.8 ± 7.0 dyne/cm 
Density : 1.15 ± 0.1 g/cm3 
Dielectric Constant : Not available 
Polarizability : 39.03± 0.5 10-24cm3 
Monoisotopic Mass : 331.132077 Da 
Nominal Mass  : 331 Da 
Average Mass  : 331.3679 Da 
M+  : 331.131528 Da 
M-  : 331.132625 Da 
[M+H]+  : 332.139353 Da 
[M+H]-  : 332.14045 Da 
[M-H]+  : 330.123703 Da 
[M-H]-  : 330.1248 Da 
 
                                                      Results and Discussion  
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RK 4: IR SPECTRUM 
 
 
N
NHO
N
O
 
 
 
 
 
Wave number cm-1 Functional group Remarks 
3034.03 C-H stretching Aromatic 
1656.85 C=O stretching Amide 
3408.22 N-H stretching Amide 
1608.63 C=N stretching Aromatic (Ring in) 
2360.87 C=N stretching Aromatic (Ring out) 
2908.65 C-CH2 stretching Methylene group. 
1492.90 C=C stretching Aromatic 
 
                                                      Results and Discussion  
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RK 4: GC – MS SPECTRUM  
 
 
Actual Molecular Mass : 331.36 g/Mol 
Expected Molecular Mass: 331.002 g/Mol 
                                                      Results and Discussion  
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RK 4: H
1
 NMR SPECTRUM 
 
 
  NO OF PROTONS     TYPE OF PEAKS 
 
      δ  VALUE 
 
    2  Singlet 5.1ppm 
   14 Multiplet      6.9-8.9ppm 
    1  Singlet 12.1ppm 
 
 
                                                      Results and Discussion  
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6.  N-benzoyl-N'-[(1E,2E)-3-phenylprop-2-en-1-ylidene]pyridine- 
 4- carbohydrazide   
N
NHO
N
Cl
Cl
 
     RK5 
PHYSICO-CHEMICAL PROPERTIES 
Description : Off  Yellowish White Solid 
Solubility : Insoluble in water, sparingly soluble in ethanol.  
Freely soluble in methanol, DMSO 
Melting Point : 189°C 
Molecular Formula : C13H9Cl2N3O  
Formula Weight : 294.13606 g/Mol 
Composition : C(53.08%) H(3.08%) Cl(24.11%) N(14.29%) O(5.44%) 
Molar Refractivity : 76.57 ± 0.5 cm3 
Molar Volume : 214.9± 7.0 cm3 
Parachor : 569.3± 8.0 cm3 
Index of Refraction : 1.631± 0.05 
Surface Tension : 49.2 ± 7.0 dyne/cm 
Density : 1.36 ± 0.1 g/cm3 
Dielectric Constant : Not available 
Polarizability : 30.35± 0.5 10-24cm3 
Monoisotopic Mass : 293.012267 Da 
Nominal Mass  : 293 Da 
Average Mass  : 294.1361 Da 
M+  : 293.011719 Da 
M-  : 293.012816 Da 
[M+H]+  : 294.019544 Da 
[M+H]-  : 294.020641 Da 
[M-H]+  : 292.003894 Da 
[M-H]-  : 292.004991 Da 
                                                      Results and Discussion  
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RK 5: IR SPECTRUM 
 
  N
NHO
N
Cl
Cl
 
 
 
 
 
 
 
Wave number cm-1 Functional group Remarks 
3088.03, 3066.82 C-H stretching Aromatic 
1678.07 C=O stretching Amide 
3203.76 N-H stretching Amide 
1589.34 C=N stretching Aromatic (Ring in) 
2360.87 C=N stretching Aromatic (Ring out) 
750.31 C-Cl stretching Halide group. 
1390.68 C=C stretching Aromatic 
 
                                                      Results and Discussion  
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RK 5: GC – MS SPECTRUM  
 
 
Actual Molecular Mass : 294.13 g/Mol 
Expected Molecular Mass : 293.85 g/Mol 
                                                      Results and Discussion  
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RK 5: H
1
 NMR SPECTRUM 
 
 NO OF PROTONS   TYPE OF PEAKS 
 
    δ  VALUE 
 
   2 Singlet       2.5ppm 
   5 Multiplet    7.2-8.1ppm 
   3 Doublet    8.7-8.9ppm 
   1 Doublet       12.3ppm 
 
                                                      Results and Discussion  
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7. N'-{(E)-[4-(benzyloxy)phenyl]methylidene}pyridine-3-carbohydrazide 
N
NHO
N
O
 
RK6 
PHYSICO-CHEMICAL PROPERTIES 
Description : Pale Yellowish Crystals 
Solubility : Insoluble in water, sparingly soluble in ethanol.  
Freely soluble in methanol, DMSO 
Melting Point : 119°C 
Molecular Formula : C20H17N3O2 
Formula Weight : 331.36788 g/Mol 
Composition : C(72.49%) H(5.17%) N(12.68%) O(9.66%) 
Molar Refractivity : 98.47± 0.5 cm3 
Molar Volume : 286.8± 7.0 cm3 
Parachor : 746.2± 8.0 cm3 
Index of Refraction : 1.602± 0.05 
Surface Tension : 45.8 ± 7.0 dyne/cm 
Density : 1.15 ± 0.1 g/cm3 
Dielectric Constant : Not available 
Polarizability : 39.03± 0.5 10-24cm3 
Monoisotopic Mass : 331.132077 Da 
Nominal Mass  : 331 Da 
Average Mass  : 331.3679 Da 
M+  : 331.131528 Da 
M-  : 331.132625 Da 
[M+H]+  : 332.139353 Da 
[M+H]-  : 332.14045 Da 
[M-H]+  : 330.123703 Da 
[M-H]-  : 330.1248 Da 
                                                      Results and Discussion  
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RK 6: IR SPECTRUM 
 
  
N
NHO
N
O
 
 
 
 
 
 
Wave number cm-1 Functional group Remarks 
3012.81 C-H stretching Aromatic 
1649.14 C=O stretching Amide 
3284.77 N-H stretching Amide 
1608.63 C=N stretching Aromatic (Ring in) 
2360.87 C=N stretching Aromatic (Ring out) 
2908.65 C-CH2 stretching Methylene group. 
1510.26 C=C stretching Aromatic 
 
                                                      Results and Discussion  
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RK 6: GC-MS  SPECTRUM 
 
 
Actual Molecular Mass : 331.36 g/Mol 
Expected Molecular Mass: 331.36 g/Mol 
                                                      Results and Discussion  
 
Department of Pharmaceutical Chemistry, COP, MMC Page 105 
 
RK 6: H
1
 NMR SPECTRUM 
 
 
 NO OF PROTONS   TYPE OF PEAKS 
 
     δ  VALUE 
 
   1  Singlet         2.5ppm 
   2 Doublet         5.1ppm 
  13 Doublet       6.9-9.3ppm 
   1  Singlet          11.9ppm 
                                                      Results and Discussion  
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8. N'-[(E)-(3,4-dichlorophenyl)methylidene]pyridine-3-carbohydrazide 
N
NHO
N
Cl
Cl
 
RK7 
PHYSICO-CHEMICAL PROPERTIES 
Description : Pale Yellow Crystals 
Solubility : Insoluble in water, sparingly soluble in ethanol. 
Freely soluble in methanol, DMSO 
Melting Point : 136°C 
Molecular Formula : C13H9Cl2N3O  
Formula Weight : 294.13606 g/Mol 
Composition : C(53.08%) H(3.08%) Cl(24.11%) N(14.29%) O(5.44%) 
Molar Refractivity : 76.57 ± 0.5 cm3 
Molar Volume : 214.9± 7.0 cm3 
Parachor : 569.3± 8.0 cm3 
Index of Refraction : 1.631± 0.05 
Surface Tension : 49.2 ± 7.0 dyne/cm 
Density : 1.36 ± 0.1 g/cm3 
Dielectric Constant : Not available 
Polarizability : 30.35± 0.5 10-24cm3 
Monoisotopic Mass : 293.012267 Da 
Nominal Mass  : 293 Da 
Average Mass  : 294.1361 Da 
M+  : 293.011719 Da 
M-  : 293.012816 Da 
[M+H]+  : 294.019544 Da 
[M+H]-  : 294.020641 Da 
[M-H]+  : 292.003894 Da 
[M-H]-  : 292.004991 Da 
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RK 7: IR SPECTRUM  
 
  
N
NHO
N
Cl
Cl
 
  
 
 
 
 
 
 
 
Wave number cm-1 Functional group Remarks 
3080.32 C-H stretching Aromatic 
1664.57 C=O stretching Amide 
3336.85 N-H stretching Amide 
1597.06 C=N stretching Aromatic (Ring in) 
2360.87 C=N stretching Aromatic (Ring out) 
725.23 C-Cl stretching Halide group. 
1597.23 C=C stretching Aromatic 
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RK 7: GC – MS SPECTRUM  
 
 
Actual Molecular Mass  : 294.13 g/Mol 
Expected Molecular Mass : 293.85 g/Mol 
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RK 7: H
1
 NMR SPECTRUM 
 
 
  NO OF PROTONS    TYPE OF PEAKS 
 
     δ  VALUE 
 
    1 Singlet        2.4ppm 
    3 Sextet     6.9-7.7ppm 
    4 Multiplet      7.8-9.2ppm 
    1 Singlet       12.1ppm 
                                                      Results and Discussion  
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9. N'-[(E)-(2-methyl-1H-indol-3-yl)methylidene]pyridine-4-carbohydrazide 
N
NHO
N
N
H
CH3
 
RK8 
PHYSICO-CHEMICAL PROPERTIES 
Description : Dark Yellow Crystals 
Solubility : Insoluble in water, sparingly soluble in ethanol.  
Freely soluble in methanol, DMSO 
Melting Point : 242°C 
Molecular Formula : C16H14N4O 
Formula Weight : 278.30856 g/Mol 
Composition : C(69.05%) H(5.07%) N(20.13%) O(5.75%) 
Molar Refractivity : 81.51 ± 0.5 cm3 
Molar Volume : 219.9± 7.0 cm3 
Parachor : 584.9± 8.0 cm3 
Index of Refraction : 1.663± 0.05 
Surface Tension : 50.0 ± 7.0 dyne/cm 
Density : 1.26 ± 0.1 g/cm3 
Dielectric Constant : Not available 
Polarizability : 32.31± 0.5 10-24cm3 
Monoisotopic Mass : 278.116761 Da 
Nominal Mass : 278 Da 
Average Mass  : 278.3086 Da 
M+  : 278.116212 Da 
M-  : 278.11731 Da 
[M+H]+  : 279.124038 Da 
[M+H]-  : 279.125135 Da 
[M-H]+  : 277.108387 Da 
[M-H]-  : 277.109485 Da 
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RK 8: IR SPECTRUM 
 
  N
NHO
N
N
H
CH3
 
 
 
 
 
 
 
 
 
Wave number cm-1 Functional group Remarks 
3047.53 C-H stretching Aromatic 
1664.57 C=O stretching Amide 
3383.14 N-H stretching Amide 
1598.99 C=N stretching Aromatic (Ring in) 
2279.86 C=N stretching Aromatic (Ring out) 
2852.72 C-H stretching in Methyl Methyl group. 
1548.84 C=C stretching Aromatic 
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RK 8: GC – MS SPECTRUM 
 
 
Actual Molecular Mass : 278.30 g/Mol 
Expected Molecular Mass : 280.00 g/Mol 
                                                      Results and Discussion  
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RK 8: H
1
 NMR SPECTRUM 
 
 
  NO OF PROTONS    TYPE OF PEAKS 
 
      δ  VALUE 
 
    3  Doublet      2.4-2.6ppm 
    9  Multiplet      6.8-8.8ppm 
    1   Doublet     10.8-10.9ppm 
                                                      Results and Discussion  
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10. N'-[(E)-(4-hydroxyphenyl)methylidene]pyridine-3-carbohydrazide 
N
NHO
N
OH
 
 RK9  
PHYSICO-CHEMICAL PROPERTIES 
Description : Pale Yellow Crystals 
Solubility : Insoluble in water, sparingly soluble in ethanol.  
Freely soluble in methanol, DMSO 
Melting Point : 215°C 
Molecular Formula : C13H11N3O2 
Formula Weight : 241.24534 g/Mol 
Composition : C(64.72%) H(4.60%) N(17.42%) O(13.26%) 
Molar Refractivity : 68.22 ± 0.5 cm3 
Molar Volume : 193.5± 7.0 cm3 
Parachor : 517.3± 8.0 cm3 
Index of Refraction : 1.622± 0.05 
Surface Tension : 50.9 ± 7.0 dyne/cm 
Density : 1.24± 0.1 g/cm3 
Dielectric Constant : Not available 
Polarizability : 27.04± 0.5 10-24cm3 
Monoisotopic Mass : 241.085127 Da 
Nominal Mass  : 241 Da 
Average Mass  : 241.2453 Da 
M+  : 241.084578 Da 
M-  : 241.085675 Da 
[M+H]+  : 242.092403 Da 
[M+H]-  : 242.0935 Da 
[M-H]+  : 240.076753 Da 
[M-H]- : 240.07785 Da 
                                                      Results and Discussion  
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RK 9: IR SPECTRUM 
 
      
N
NHO
N
OH
 
 
 
 
 
Wave number cm-1 Functional group Remarks 
3072.60, 3012.81 C-H stretching Aromatic 
1658.78 C=O stretching Amide 
3421.72 N-H stretching Amide 
1598.99, 1581.63 C=N stretching Aromatic (Ring in) 
2360.87 C=N stretching Aromatic (Ring out) 
3527 O-H stretching Hydroxy group. 
1514.72 C=C stretching Aromatic 
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RK 9: GC-MS  SPECTRUM 
 
 
Actual Molecular Mass : 241.24 g/Mol 
Expected Molecular Mass : 241.24g/Mol 
                                                      Results and Discussion  
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RK 9: H
1
 NMR SPECTRUM 
 
 
   NO OF PROTONS    TYPE OF PEAKS 
 
     δ  VALUE 
 
    1 Singlet        2.5ppm 
    3 Singlet        3.55ppm 
    6 Multiplet       6.8-9.7ppm 
    1 Doublet        11.8ppm 
                                                      Results and Discussion  
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RESULTS OF BIOLOGICAL SCREENING 
The synthesized compounds were screened for their in-vitro anti mycobacterial 
activity by means of alamar blue assay. The compounds were tested in the concentration 
range of 100 to 0.8 μg/ml against M.tuberculosis H37Rv strain grown in Middlebrook 
7H9 broth in 96 well titre plate. Pyrazinamide-3.125μg/ml, Ciprofloxacin- 3.125μg/ml  
and Streptomycin- 6.25μg/ml were used as standards for comparison. A blue color in 
the well was interpreted as no bacterial growth so it is termed as sensitive, and pink  
color was scored as growth and is referred as resistant. The MIC was defined as lowest 
drug concentration which prevented the color change from blue to pink.  
MABA REPORT OF THE SYNTHESISED COMPOUNDS 
Sample 
100 
µg/ml 
50 
µg/ml 
25 
µg/ml 
12.5 
µg/ml 
6.25 
µg/ml 
3.12 
µg/ml 
1.6 
µg/ml 
0.8 
µg/ml 
200 
ng/ml 
RK-1     S     S     S     S     S    R    R    R     R 
RK-2     S     S     S     S     S    S    R    R     R 
RK-2a     S     S     R     R     R    R    R    R     R 
RK-3     S     S     R     R     R    R    R    R     R 
RK-4     S     S     R     R     R    R    R    R     R 
RK-5     S     S     R     R     R    R    R    R     R 
RK-6     S     S     R     R     R    R    R    R     R 
RK-7     S     S     R     R     R    R    R    R     R 
RK-8     S     S     R     R     R    R    R    R     R 
RK-9     S     S     R     R     R    R    R    R     R 
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STANDARD DRUG PHOTOGRAPH 
 
SYNTHESISED COMPOUND PHOTO GRAPH 
Sampl
e 
100 
µg/ml 
50 
µg/ml 
25 
µg/ml 
12.5 
µg/ml 
6.25 
µg/ml 
3.12 
µg/ml 
1.6 
µg/ml 
0.8 
µg/ml 
RK-1 
 
 
 
 
RK-2 
RK-2a 
RK-3 
RK-4 
RK-5 
RK-6 
RK-7 
RK-8 
RK-9 
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RESULTS OF TOXICITY RISK ASSESSMENT  
All the data set molecules were subjected to the toxicity risk assessment by using 
OSIRIS property Explorer . It allows drawing chemical structures and also calculates 
various drug relevant properties whenever a structure is valid. The properties are 
cLogP, solubility, molecular weight,total polar surface area ( TPSA), druglikeness and 
drug score. 
INSILICO TOXICITY PREDICTION 
Prediction results are color coded in which the red colour shows high risks with 
undesired effects like mutagenicity and reproductive effects or a poor intestinal 
absorption and yellow colour shows moderate risks with undesired effects and green 
colour indicates drug-conform behavior. 
  
RK 1 RK 2 
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RK 2a RK 3 
 
 
 
 
  
RK 4 RK 5 
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RK 6 RK 7 
 
 
 
  
RK 8 RK 9 
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DISCUSSION 
 The synthesised compound RK1and RK2a showed a 100% purity due to 
presence of  single peak in LC-MS spectrum and GC-MS spectrum 
respectively, and its purity were confirmed by sharp melting point at 
165°C and 88°C 
 The synthesised compounds RK3, RK4, RK5, RK6, RK7, RK8 and RK9 
showed above 90% purity due to presence of two or three peaks in 
spectrum , and its purity confirmed by sharp melting points.  
 The invitro studies of  synthesised compounds RK1  and RK2 were active 
at 6.25 µg/ml (MIC) and 3.125 µg/ml (MIC), which were compaed with 
the known standard drugs (MIC). 
 The all compounds of RK2a, RK3, RK4, RK5, RK6, RK7, RK8, and RK9 
were active at 50 µg/ml (MIC), which were not correlated with the any of 
the known standard drugs (MIC). 
 Toxicity  prediction of synthesised compounds were performed by Osiris 
property explorer and its toxicity characteristics were observed.  
SYNTHESISE
D 
COMPOUNDS 
MUTAGENI
C 
 
TUMAROGENI
C 
IRRITAN
T 
REPRODUCTIV
E EFFECTS 
RK1 − + − + 
RK2 − − − − 
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 NOTE:  (+) – TOXICITY and (−) NON-TOXICITY 
 
RK2a − − − − 
RK3 − − − − 
RK4 − − − − 
RK5 − − − − 
RK6 − + − + 
RK7 − − − − 
RK8 − + − + 
RK9 − − − − 
                                                             Summary and Conclusion 
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6. SUMMARY AND CONCLUSION 
        SUMMARY 
Diaminopimelate decarboxylase (LysA), a critical enzyme for the lysine 
biosynthesis of Mycobacterium tuberculosis was chosen for study after review of 
literature.  
Candidate molecules were designed and docked against 3C5Q protein using 
Argus lab 4.0software.  
Molecules with good Docking score (lower binding energy) and interactions 
were shortlisted for synthesis. The reaction conditions were optimized.  
The selected molecules were subjected to Toxicity prediction assessments by 
OSIRIS software. Only those molecules which did not indicate any form of toxicity 
were selected for synthesis.  
Compounds were synthesized by conventional method and labeled as RK 1, RK 
2, RK 2a, RK 3, RK 4, RK 5, RK 6, RK 7, RK 8 and RK 9.  
Purity of the synthesized compounds was ensured by repeated recrystallization 
and purified by column and gas chromatography. Further the compounds were evaluated 
by TLC and Melting point determination.  
The structures of the compounds were assigned on the basis of IR, NMR and 
MASS spectral data.  
The pure compounds were screened for IN-VITRO Anti- tubercular activity by 
Micro plate Alamar Blue Assay (MABA). All compounds showed  significant anti -
mycobacterium activity.  
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The synthesized compounds were active at 3.125 – 50 µ g/ml, which is 
comparable to the known anti-TB drugs: MIC of Pyrazinamide - 3.125µg/ml, MIC of 
Ciprofloxacin - 3.125µg/ml and MIC of Streptomycin - 6.25µg/ml.  
Though the synthesised molecules were designed for the target Diaminopimelate 
Decarboxylase (LysA), the molecules were docked against other critical anti -tubercular 
targets like Alpha 1,4-N- Acetyl glycosaminyl transferase(1,4NAGT), D-3 
Phosphoglycerate dehydrogenase(D3PD), Pyridoxamine 5-phosphate oxidase(P5PO) 
and D-Alanyl  D-Alanine carboxypeptidase(DADAC). 
It is found that compounds RK1, RK2, RK2a, RK3, RK4, RK5, RK6, RK7, RK8 
and RK9 show better G-Score for the targets  Alpha 1,4-N-Acetyl glycosaminyl 
transferase,D-3 Phosphoglycerate dehydrogenase, Pyridoxamine 5-phosphate oxidase 
and D-Alanyl  D-Alanine carboxypeptidase.  
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CONCLUSION 
Our work concludes that based on docking G-Score our synthesized molecules 
were effective in inhibiting the target enzyme Diaminopimelate decarboxyl ase 
(LysA)Score, which were important for the lysine biosynthesis of Mycobacterium 
tuberculosis.  
Through the invitro studies, it were proved that the synthesised compounds RK1 
and RK2 showed the MIC of 6.25µg/ml and 3.125µg/ml which were equal to the known 
concentration of the standard drugs streptomycin 6.25µg/ml and pyrazinamide 
3.125µg/ml as well as ciprofloxacin3.125µg/ml. 
All other compounds except RK1 and RK2 were active at 50µg/ml which were 
not correlated with any concentration of the known standard drugs. 
The molecules were also docked with the some other enzymes, Based on the 
good G-Score the synthesised molecules were effective in inhibiting the target enzymes 
like 1,4 NAGT, D-3-PD, P-5-PO and DADAC, which were  important for respectively 
the Arginine biosynthesis for regulates cell wall and cell processes , 6-Serine 
biosynthesis for cell signaling, Pyridoxine synthesis for intermediatory metabolism and 
respiration and Peptidoglycan synthesis for cell wall and cell processes of 
Mycobacterium tuberculosis. 
 
  Future Scope of the Study  
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FUTURE SCOPE OF THE STUDY 
This work may be further extended to the following areas  
 Screening the synthesised compounds for its activity against various other 
multifunctional drug targets of M.tuberculosis based on the good G-Score 
and ligand interaction.
 Carrying out further modifications in the structure, in case, the compound 
does not show the predicted activity against the target.
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